<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31019473</article-id>
<article-id pub-id-type="pmc">6459027</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2019.00207</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurological, Psychiatric, and Biochemical Aspects of Thiamine Deficiency in Children and Adults</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dhir</surname>
<given-names>Shibani</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/672843" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tarasenko</surname>
<given-names>Maya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/668231" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Napoli</surname>
<given-names>Eleonora</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/115841" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giulivi</surname>
<given-names>Cecilia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/77782" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup><institution>Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis</institution>, <addr-line>Davis, CA</addr-line>, <country>United States</country></aff>
<aff id="aff2">
<sup>2</sup><institution>Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis</institution>, <addr-line>Davis, CA</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Shannon Rose, University of Arkansas for Medical Sciences, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Brahim Tabarki, University of Sousse, Tunisia; Majid Alfadhel, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia</p>
</fn>
<corresp id="fn001">*Correspondence: Cecilia Giulivi, <email xlink:href="mailto:cgiulivi@ucdavis.edu" xlink:type="simple">cgiulivi@ucdavis.edu</email>
</corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>†These authors have contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>207</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Dhir, Tarasenko, Napoli and Giulivi</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Dhir, Tarasenko, Napoli and Giulivi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Thiamine (vitamin B1) is an essential nutrient that serves as a cofactor for a number of enzymes, mostly with mitochondrial localization. Some thiamine-dependent enzymes are involved in energy metabolism and biosynthesis of nucleic acids whereas others are part of the antioxidant machinery. The brain is highly vulnerable to thiamine deficiency due to its heavy reliance on mitochondrial ATP production. This is more evident during rapid growth (i.e., perinatal periods and children) in which thiamine deficiency is commonly associated with either malnutrition or genetic defects. Thiamine deficiency contributes to a number of conditions spanning from mild neurological and psychiatric symptoms (confusion, reduced memory, and sleep disturbances) to severe encephalopathy, ataxia, congestive heart failure, muscle atrophy, and even death. This review discusses the current knowledge on thiamine deficiency and associated morbidity of neurological and psychiatric disorders, with special emphasis on the pediatric population, as well as the putative beneficial effect of thiamine supplementation in autism spectrum disorder (ASD) and other neurological conditions.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorders</kwd>
<kwd>brain</kwd>
<kwd>depressive disorders</kwd>
<kwd>encephalomyopathies</kwd>
<kwd>Krebs cycle</kwd>
<kwd>pentose phosphate pathway</kwd>
<kwd>thiamine transporter</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="156"></ref-count>
<page-count count="15"></page-count>
<word-count count="8419"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The essential nutrient thiamine (vitamin B1) is a water-soluble, sulfur-containing vitamin belonging to the vitamin B complex family (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>). Not being endogenously synthesized, the only available source of thiamine is dietary (beef, poultry, cereals, nuts, and beans). The body does not store thiamine in levels &gt;30 mg, and the half-life for thiamine is only 9–18 days. For an average of ∼2,000 kcal consumed daily, the minimum thiamine requirement is calculated at 0.66 mg (<xref ref-type="bibr" rid="B1">1</xref>), although the recommended daily intake for adult men and women is 1.2 and 1.1 mg, respectively (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). During pregnancy or breast-feeding, this requirement increases to 1.4 mg/day (<xref ref-type="bibr" rid="B1">1</xref>). In children, the recommended dietary allowance (RDA) is age-dependent and spanning from 0.2 mg (from birth up to 6 months old) to 0.6 mg (from 6 months old to 8 years old) (<xref ref-type="bibr" rid="B3">3</xref>). In the human body, thiamine-rich tissues are skeletal muscles, heart, liver, kidney, and brain (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Thiamine metabolism. <bold>(A)</bold> Chemical structure of thiamine and phosphorylated derivatives. <bold>(B)</bold> Absorption and cellular uptake of thiamine. Dietary thiamine is mainly in the form of phosphate derivatives and, before absorption, these are converted to free thiamine by intestinal phosphatases. Mammalians utilize THTR1 and THTR2 to transport thiamine. The THTR1 appears to function in the micromolar range, whereas the THTR-2 appears to function in the nanomolar range. Both transporters are expressed in the human small and large intestine, and the expression of THTR1 is higher than that of THTR2, with THTR1 found at both the apical and basolateral membranes of enterocytes (somewhat higher expression at the latter compared to the former domain). Expression of the THTR2 protein was found to be restricted to the apical membrane domain only [see (<xref ref-type="bibr" rid="B5">5</xref>) and references therein]. Free thiamine is converted to TPP by the action of TPK1 in the cytosol and dephosphorylation of TPP to TMP and thiamine by ACPP. At higher concentrations of thiamine, simple passive diffusion takes place [see (<xref ref-type="bibr" rid="B6">6</xref>) and references therein]. From blood, thiamine is taken up by either transporter (THTR1 or THTR2). Both carriers are widely distributed in the body, but the levels differ in different tissues. Once inside the target cells, thiamine is phosphorylated to TPP by TPK1 and to TTP by TDPK. Both TPP and TTP can be dephosphorylated by ACPP and THTPA, respectively. TPP in the cytosol is utilized as a cofactor for TKT, but it is also required as a cofactor in the mitochondrial compartment; hence, the mitochondrial SLC25A19 exists at the inner mitochondrial membrane. TPP must be bound to HACL1 and HACL2 for its transport to the peroxisomes. Abbreviations: ACPP, prostatic acid phosphatase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; T, thiamine; TDPK, thiamine diphosphokinase; THTPA, thiamine triphosphatase; THTR, thiamine transporter; TMP, thiamine monophosphate; TPP, thiamine pyrophosphate. <bold>(C)</bold> Pathways involving TPP-dependent enzymes. In the cytosol, TPP is the cofactor of transketolase (TKT), an enzyme involved in the pentose phosphate pathway (PPP). The PPP produces nicotinamide adenine dinucleotide phosphate (NADPH) and ribose 5-phosphate (R5P), essential for antioxidant defense and fatty acid synthesis, and precursor in the biosynthesis of nucleotides, respectively. In mitochondria, TPP acts as a cofactor for branched-chain α-ketoacid dehydrogenase (BCKDH) complex, pyruvate dehydrogenase (PDH) complex, and α-ketoglutarate dehydrogenase. In peroxisomes, TPP is a cofactor for 2-hydroxyacyl-CoA lyase 1 (HACL1) as part of the fatty acid α-oxidation pathway.</p>
</caption>
<graphic xlink:href="fpsyt-10-00207-g001"></graphic>
</fig>
<p>Despite the availability of dietary thiamine in wealthy countries, thiamine deficiency represents an important and usually overlooked issue. In developed countries, the predominant use of industrial food processing often depletes thiamine content along with other vitamins and nutrients. An increased consumption of processed food in the form of simple carbohydrates, not supplemented with adequate levels of thiamine, has been named “high calorie malnutrition” (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Thus, despite the caloric density, the diet is often of poor nutrition quality and does not meet recommended dietary guidelines for micronutrient intake, making this an at-risk population for micronutrient malnutrition (<xref ref-type="bibr" rid="B8">8</xref>). For instance, at least 29% of obese subjects that will undergo bariatric surgery have been reported as thiamine deficient (<xref ref-type="bibr" rid="B9">9</xref>). This condition highlights the fine balance between adequate caloric intake and balanced nutritional diet. As thiamine is a key factor in the metabolism of glucose, an increased carbohydrate intake will proportionally increase thiamine’s dietary demand (a minimum of 0.33 mg per 1,000 kcal) (<xref ref-type="bibr" rid="B1">1</xref>). Thus, rather than focusing on thiamine’s RDA, it is critical to match its intake with carbohydrate consumption as well as total caloric intake.</p>
<p>In developing countries, thiamine deficiency remains a widespread concern due to high rates of white rice consumption (<xref ref-type="bibr" rid="B3">3</xref>). As home-pounding techniques are replaced with industrial rice milling and processing, essential nutrients (such as thiamine) within the bran are stripped away (<xref ref-type="bibr" rid="B10">10</xref>). Asian countries consume about 90% of the rice produced worldwide, fulfilling an estimated 60% of the population’s daily dietary energy intake requirement, and consequently, thiamine deficiency has become prevalent in the 15% of the adolescent population (using the most conservative approximation) (<xref ref-type="bibr" rid="B11">11</xref>). Thiamine deficiency may develop by ingesting diets either contaminated with thiamine-metabolizing enzymes (e.g., thiaminase) (<xref ref-type="bibr" rid="B12">12</xref>) or that underwent thiamine inactivation by heat and/or sulfur dioxide (<xref ref-type="bibr" rid="B13">13</xref>). Heavy consumption of tannin-containing or food rich in caffeine, theobromine, and theophylline (such as those present in coffee, chocolate, and tea, respectively) can inactivate thiamine, thereby compromising the thiamine status (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>Other risk factors that increase the likelihood of insufficient thiamine intake include aging, economic status, eating disorders, medical conditions affecting the gastrointestinal tract, subjects receiving parental nutrition, bariatric surgery, diabetes, and alcohol abuse (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B23">23</xref>). Unmet needs for increasing the nutritional intake of thiamine are reported during lactation, pregnancy, and increased physical activity (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B24">24</xref>). During lactation, infants have increased risks of developing beriberi from newly deficient but asymptomatic mothers (<xref ref-type="bibr" rid="B11">11</xref>). For instance, 27% of women of childbearing age are considered thiamine deficient in Cambodia, with 38% of infants being diagnosed as severely deficient in thiamine, a critical issue that contributes significantly to the mortality of 3-month-old babies (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>However, even in the presence of an adequate thiamine intake, its deficiency can result from genetic factors, i.e., pathogenic gene mutations in key regulators of the thiamine pathway, including thiamine pyrophosphokinase 1 (TPK1), thiamine diphosphate kinase (TDPK), thiamine triphosphatase (THTPA), and thiamine transporters (SLC25A19, SLC19A2/THTR1, and SLC19A3/THTR2; <xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>). More recently, the organic cation transporter 1 (OCT1) has been claimed to act as a hepatic thiamine transporter (<xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Regardless of the underlying cause, thiamine deficits may have severe detrimental effects, with most of the symptoms manifesting at the neurological level (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Thiamine deficiency might cause brain tissue injury by inhibiting brain energy utilization given the critical role of thiamine-dependent enzymes associated within glucose utilization (<xref ref-type="bibr" rid="B27">27</xref>). This is supported by the significant rate of thiamine uptake by the blood–brain barrier emphasizing the high brain demand for thiamine and the need for its supply to sustain adequate brain functions (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>), especially in those brain areas with both high metabolic demands and high thiamine turnover (<xref ref-type="bibr" rid="B30">30</xref>–<xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>This review will discuss the physiological and biochemical bases of thiamine metabolism and explore the pathophysiological implications of thiamine deficiency. In particular, we will highlight the effect of thiamine supplementation as a therapeutic strategy in the management of neurological disorders, with special emphasis on the pediatric population.</p>
</sec>
<sec id="s2">
<title>Biochemical Basis of Thiamine’s Cellular Role</title>
<sec id="s2_1">
<title>Dietary Availability, Absorption, and Cellular Uptake</title>
<p>As with most hydrophilic micronutrients, thiamine absorption occurs mainly in the jejunum (<xref ref-type="bibr" rid="B33">33</xref>). Throughout the digestive tract, dietary proteins get hydrolyzed, releasing thiamine. In the intestinal lumen, alkaline phosphatases catalyze the hydrolysis of thiamine-phosphorylated derivatives into free thiamine (<xref ref-type="bibr" rid="B34">34</xref>). Unphosphorylated, free thiamine at concentrations higher than 1 µM enters the enterocyte by passive diffusion, whereas at lower levels, it is transported <italic>via</italic> the saturable thiamine/H<sup>+</sup> antiport system (thiamine transporter 1 or THTR1) through an energy-dependent process (<xref ref-type="bibr" rid="B33">33</xref>). Under conditions of thiamine deficiency, an upregulation of the expression of the thiamine transporter 2 (THTR2) was observed in Caco2 cells in culture, suggesting that diet can modulate the expression of this transporter (<xref ref-type="bibr" rid="B35">35</xref>). Within the enterocyte, thiamine is phosphorylated to thiamine pyrophosphate (TPP) by TPK1. Then, most TPP is dephosphorylated to thiamine monophosphate (TMP) to cross the basal membrane of the enterocyte. The TMP is released into the bloodstream through an ATPase-dependent transport system (<xref ref-type="bibr" rid="B36">36</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>). Free thiamine can also reach the bloodstream <italic>via</italic> the thiamine transporter 2 (THTR2) located mainly at the basolateral membrane of the enterocyte. Once in blood, while very low levels of TMP and thiamine circulate free in plasma or serum, more than 90% of the phosphorylated thiamine (in the form of TPP) is present in erythrocytes and leukocytes (<xref ref-type="bibr" rid="B37">37</xref>). Notably, the isoform 3 of the carrier SLC44A4 has recently been described as a TPP carrier in the colon. Originally, SLC44A4 was described as a choline transporter linked to the non-neuronal synthesis of choline (<xref ref-type="bibr" rid="B38">38</xref>) and required to the efferent innervation of hair cells in the olivocochlear bundle for the maintenance of physiological function of outer hair cells and the protection of hair cells from acoustic injury (<xref ref-type="bibr" rid="B39">39</xref>). Recent evidence indicates that this carrier may mediate the absorption of microbiota-generated TPP (especially in infants) and contribute to host thiamine homeostasis (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>The cellular uptake of thiamine from the bloodstream can be mediated by any of the two high-affinity carriers: THTR1 [encoded by <italic>SLC19A2</italic> (<xref ref-type="bibr" rid="B41">41</xref>)] and THTR2 [encoded by <italic>SLC19A3</italic> (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>)]. These transporters are ubiquitously expressed (<xref ref-type="bibr" rid="B42">42</xref>–<xref ref-type="bibr" rid="B44">44</xref>), but THTR1 is most abundant in the intestine, skeletal muscle, nervous system, and eye followed by the placenta, liver, and kidney, whereas THTR2 is located mostly in adipose tissue, breast tissue, liver, lymphocytes, spleen, gallbladder, placenta, pancreas, and brain (information collected from GeneCards). Once transported intracellularly, free thiamine is rapidly phosphorylated to TPP by thiamine pyrophosphokinase (TPK1). A second kinase, TDPK, adds a phosphate group to TPP to generate thiamine triphosphate (TTP). TPP and TTP can be dephosphorylated to, respectively, TMP and TPP by phosphatases [Prostatic Acid Phosphatase (ACPP) and THTPA, respectively; <xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>].</p>
</sec>
<sec id="s2_2">
<title>Biochemical Roles of Phosphorylated Forms of Thiamine</title>
<p>Up to 90% of the total thiamine in the body remains in its diphosphate, metabolically active form (TPP), whereas the rest is found as TMP and TTP (<xref ref-type="bibr" rid="B45">45</xref>). TPP is a cofactor of several thiamine-dependent enzymes involved in carbohydrate and fatty acid metabolism, namely, cytosolic transketolase (TKT), peroxisomal 2-hydroxyacyl-CoA lyase 1, and three mitochondrial enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and branched-chain α-ketoacid dehydrogenase complexes; <bold>Figure 1C</bold>). As the biochemical role of TPP is well understood, the biological significance and contribution of TTP is not entirely clear. It was previously considered to be a specific neuroactive form of thiamine, but more recently, it has been reported that TTP (which is ∼10% of the total brain thiamine pool) is involved in membrane excitability and nerve conduction by acting as a modulator of the permeability of sodium chloride channels (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B46">46</xref>).</p>
<sec id="s2_2_1">
<title>Intracellular Location of TPP-Dependent Enzymes</title>
<sec id="s2_2_1_1">
<title>Cytosol</title>
<p>In the cytosol, TPP acts as a cofactor for TKT, a key enzyme of the non-oxidative branch of the pentose phosphate pathway (PPP). This metabolic pathway generates nicotinamide adenine dinucleotide phosphate (NADPH) and ribose 5-phosphate (R5P) (<xref ref-type="bibr" rid="B47">47</xref>). NADPH is a key reducing agent in biosynthetic reactions and is a co-substrate of biosynthetic enzymes (fatty acid synthesis) and antioxidant enzymes such as the glutathione peroxidase–reductase system and thioredoxin peroxidases, among others. The crucial involvement of R5P in the biosynthesis of DNA and RNA highlights the critical role of thiamine in high-proliferating tissues.</p>
<p>Based on its role in the abovementioned biochemical pathways, it is expected that thiamine deficiency will result in increased oxidative stress and lower cell proliferation, as well as decreased fatty acid synthesis (including myelin) with severe consequences especially during brain development. Consistent with this premise, thiamine deficiency decreases TKT activity and leads to PPP impairment and reduced neurogenesis in murine cortex and hippocampus during neurodevelopment (<xref ref-type="bibr" rid="B48">48</xref>).</p>
</sec>
<sec id="s2_2_1_2">
<title>Peroxisomes</title>
<p>Peroxisomes play an important role in the catabolism of hydrogen peroxide, as well as in the shortening of very long fatty acids (which cannot undergo a direct mitochondrial β-oxidation catabolism) and α-oxidation (<xref ref-type="bibr" rid="B49">49</xref>). In the latter process, the TPP-dependent enzyme 2-hydroxyacyl-CoA lyase 1 (HACL1) catalyzes the cleavage of 3-methyl-branched and straight chain 2-hydroxy long-chain fatty acids (<xref ref-type="bibr" rid="B50">50</xref>). Phytanic acid (a 3-methyl-substituted, 20-carbon branched-chain fatty acid), unlike most fatty acids, is unable to undergo β-oxidation because of an existing methyl group in the 3-position (<xref ref-type="bibr" rid="B51">51</xref>). As such, it is broken down by HACL1 by an initial α-oxidation (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). This branched-chain fatty acid is obtained through the diet, specifically from dairy products and red meat. The disruption of phytanic acid catabolism, due to inadequate levels of TPP, leads to triglyceride accumulation, which may cause deleterious effects such as cerebellar ataxia, peripheral polyneuropathy, vision and hearing loss, anosmia, and, in some instances, cardiac dysfunction and epiphyseal dysplasia (<xref ref-type="bibr" rid="B54">54</xref>). The symptoms caused by thiamine deficiency are shared by Refsum’s disease, which is caused by pathogenic mutations in <italic>HACL1</italic> (<xref ref-type="bibr" rid="B55">55</xref>). Some of the symptoms are also observed in the autosomal recessive systemic disorder Zellweger syndrome and other peroxisomal-related diseases including the neonatal adrenoleukodystrophy. Zellweger syndrome is caused by pathogenic mutations in the pexin genes, which encode for proteins essential for the assembly of functional peroxisomes. It is characterized by deficits in the peroxisomal fatty acid oxidation pathway causing severe neurological and liver dysfunction as well as craniofacial abnormalities.</p>
</sec>
<sec id="s2_2_1_3">
<title>Mitochondria</title>
<p>Most (∼90%) of the cytosolic TPP is transported into mitochondria <italic>via</italic> the mitochondrial thiamine pyrophosphate transporter [MTPPT, product of the <italic>SLC25A19</italic> gene (<xref ref-type="bibr" rid="B56">56</xref>)]. This transporter mediates the exchange of cytosolic TPP for the mitochondrial TMP; once in the cytosol, TMP is metabolized and converted back to TPP (<xref ref-type="bibr" rid="B56">56</xref>). In mitochondria, TPP is a critical cofactor for three enzymes, namely, pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and branched-chain α-ketoacid dehydrogenase (PDH, αKGDH, and BCKDH, respectively).</p>
<p>Studies in <italic>SLC25A19</italic> knockout mice and in carriers of the <italic>SLC25A19</italic> mutation, responsible for the Amish lethal microcephaly (MCPHA, see below) show, respectively, virtually undetectable and markedly reduced mitochondrial TPP levels in mouse embryonic fibroblasts and human lymphoblasts (<xref ref-type="bibr" rid="B56">56</xref>), which were completely restored upon addition of TPP to the PDH and KGDH complex assay mixtures (<xref ref-type="bibr" rid="B56">56</xref>).</p>
<sec id="s2_2_1_3_1">
<title>Pyruvate dehydrogenase complex</title>
<p>This multisubunit complex catalyzes the TPP-dependent decarboxylation of pyruvate, generating acetyl-CoA, which then enters the Krebs cycle. The regulation of PDH activity constitutes a key metabolic switch influencing fuel choice, i.e., between fatty acid oxidation and glycolytic flux (<xref ref-type="bibr" rid="B57">57</xref>). The inability to adjust the choice of fuel for metabolic energy production has been proposed to underlie the “metabolic inflexibility” leading to the morbidity of metabolic disorders (<xref ref-type="bibr" rid="B58">58</xref>). Hence, thiamine-deficiency-mediated inhibition of the PDH complex will lock the system into the oxidation of glucose to pyruvate, leading to increases in lactate and decreases in cellular ATP production (<xref ref-type="bibr" rid="B59">59</xref>). As expected, in severe cases, the metabolic deficit presents as a fatal lactic acidosis in newborns, whereas in milder cases, neurological conditions may lead to structural abnormalities in the central nervous system (CNS), seizures, mental disability, and spasticity (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>).</p>
</sec>
<sec id="s2_2_1_3_2">
<title>α-Ketoglutarate dehydrogenase complex</title>
<p>This TPP-dependent enzyme catalyzes the formation of succinyl-CoA from α-ketoglutarate in the Krebs cycle and the consequent production of reduced nicotinamide adenine dinucleotide (NADH). Low TPP levels notably decrease αKGDH activity, thereby decreasing energy production and causing glutamate to accumulate (<xref ref-type="bibr" rid="B62">62</xref>), hampering oxidative metabolism and leading to neurodegeneration (<xref ref-type="bibr" rid="B63">63</xref>).</p>
</sec>
<sec id="s2_2_1_3_3">
<title>Branched-chain α-keto dehydrogenase complex</title>
<p>The TPP-dependent BCKDH enzyme, localized at the inner mitochondrial membrane, catalyzes one of the steps of the essential branched-chain amino acid (BCAAs; leucine, isoleucine, and valine) catabolic pathway. These amino acids are required for protein synthesis, and some of their catabolic products can be used for energy production <italic>via</italic> the citric acid cycle. In addition, their carbon skeletons (except Leu) can be used as precursors for gluconeogenesis (<xref ref-type="bibr" rid="B64">64</xref>). In a thiamine deficiency experimental model, medial thalamus was the brain region that shows the lowest levels of BCKDH with fivefold accumulation of Leu. This study suggested that the lower activity of this enzyme may be responsible for thalamic neuronal cell death observed in human cases of thiamine deficiency (<xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>Similarly, a homozygous mutation in the BCKDH E1 α subunit results in the so-called maple syrup urine disease (MSUD, due to the distinct maple syrup smell to the urine as a result of keto acid buildup from unprocessed BCAA), characterized by physical and mental disabilities. A mild form of MSUD, called thiamine-responsive MSUD, is currently the only recognized variant that can be successfully treated with thiamine supplementation (OMIM 248600).</p>
</sec>
</sec>
</sec>
</sec>
</sec>
<sec id="s3">
<title>Hierarchical Order of Thiamine-Dependent Enzymatic Deficiencies: Effect of Species, Tissue, and Subcellular Compartment</title>
<p>While it could be assumed that a deficiency in a given micronutrient affects its dependent enzymes equally, experimental evidence indicates otherwise. For instance, copper deficiency severely reduces cytochrome <italic>c</italic> oxidase activity affecting copper/zinc-superoxide dismutase to a lesser extent (<xref ref-type="bibr" rid="B66">66</xref>). Moreover, this hierarchical order is also tissue-specific as different brain areas (<xref ref-type="bibr" rid="B66">66</xref>). Similarly, in the case of thiamine deficiency, the most affected brain regions seem to be cerebellum, mammillary bodies, thalamus, hypothalamus, and brainstem in adults (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B67">67</xref>). In children, MRI studies showed primary involvement of mammillary bodies as well as basal ganglia (<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>) [preferentially the striatum and, to a lesser extent, the globus pallidus (<xref ref-type="bibr" rid="B68">68</xref>)], in addition to frontal lobes (<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>With regard to thiamine deficiency, Zhao et al. showed that, in mice, thiamine deprivation for 14 days led to different degrees of enzymatic deficiencies when testing for TKT, PDH, and αKGDH activities in the cortex and hippocampus (<xref ref-type="bibr" rid="B48">48</xref>). TKT activity was significantly more reduced in both brain regions compared to both mitochondrial enzymes PDH and αKGDH (<xref ref-type="bibr" rid="B48">48</xref>). Two studies reporting on a genetic mutation in SLC19A3.1 resulted in thiamine-deficient Alaskan huskies (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B70">70</xref>). A greater reduction in TKT versus PDH activity was observed in the cortex. In the thalamus, however, PDH activity was affected twice as much as TKT activity (<xref ref-type="bibr" rid="B26">26</xref>). These studies support the concept of tissue-specific deficits of thiamine deficiency and also point to the species-specific differences that should be taken into account when making extrapolations to human studies.</p>
<p>In cases of severe thiamine deficiency, however, a broad enzymatic deficiency encompassing all three mitochondrial TPP-dependent enzymes would be expected to result in symptoms similar to those of the genetic disorder dihydrolipoamide dehydrogenase (DLDD) deficiency (OMIM 246900). This pathogenic mutation affects the E3 subunit, common to all three TPP-dependent dehydrogenases. Patients clinically present with lactic acidosis and neurodegeneration from inefficient oxidative metabolism, as well as increased BCAA concentrations and α-keto acids in the urine, with many of the same symptoms as MSUD, but with a more severe phenotype (<xref ref-type="bibr" rid="B71">71</xref>).</p>
<p>While BCKDH and HACL1 are (as indicated above) TPP-dependent enzymes, their activity is rarely reported in the context of thiamine deficiency, with the majority of studies focusing on TKT and PDH or αKGDH as indicators of oxidative stress (TKT) and mitochondrial dysfunction (PDH or αKGDH). However, a study by Navarro et al. noted significantly reduced BCKDH activity in the medial thalamus (compared to frontal cortex) accompanied by a fivefold increase in Leu levels following administration of a thiamine antagonist (<xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>The consequences of thiamine deficiency on HACL1, however, remain mostly obscure. Recent work in HACL1-deficient mice revealed the presence of an additional TPP-dependent enzyme with lyase activity, localized in the endoplasmic reticulum, able to cleave 2-hydroxyphytanoyl-CoA (<xref ref-type="bibr" rid="B72">72</xref>). This process is not exactly like the one catalyzed by the peroxisomal HACL1 and involves a hydroxylation at position C2 carried out by the fatty acid 2-hydroxylase (FA2H), followed by the cleavage catalyzed by HACL1 (<xref ref-type="bibr" rid="B73">73</xref>). More recently, an orphan enzyme (HACL2) located in the endoplasmic reticulum known as bacterial acetolactate synthase-like was reported to cleave straight chain 2-hydroxyacyl-CoAs (<xref ref-type="bibr" rid="B74">74</xref>), and it is likely to be identical to the HACL1-like enzyme. A strong inverse association of C17:0 with diabetes and cardiovascular risk has been observed, suggesting a metabolic link between α-oxidation and these diseases (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>). More research is needed to elucidate the role of HADCL1 and HADCL2 in the context of thiamine deficiency.</p>
</sec>
<sec id="s4">
<title>Defects in Genes Associated With Thiamine Metabolism</title>
<p>Pathogenic mutations in genes encoding for enzymes and transporters involved in thiamine metabolism result in symptoms similar to those found in nutrition-based thiamine deficiency and overlaps with disorders of mitochondrial dysfunction (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Those mutations affecting genes responsible for thiamine transporters 1 (<italic>SLC19A2</italic>; OMIM 249270) and 2 (<italic>SLC19A3</italic>; OMIM 607483) constitute the main cause of suboptimal intestinal thiamine absorption and, as a result, insufficient cellular distribution of thiamine through the body.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Genetic mutations affecting thiamine metabolism.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top">Name of disease</th>
<th colspan="1" rowspan="1" valign="top">Mutation</th>
<th colspan="1" rowspan="1" valign="top">Protein</th>
<th colspan="1" rowspan="1" valign="top">Age at onset</th>
<th colspan="1" rowspan="1" valign="top">Clinical symptoms</th>
<th colspan="1" rowspan="1" valign="top">Management (dose) (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">TRMA/Rogers syndrome</td>
<td colspan="1" rowspan="1" valign="top">SLC19A2</td>
<td colspan="1" rowspan="1" valign="top">THTR1</td>
<td colspan="1" rowspan="1" valign="top">Birth to adolescence</td>
<td colspan="1" rowspan="1" valign="top">Megaloblastic anemia, diabetes mellitus, sensorineural deafness, optic atrophy, congenital heart defects, short stature</td>
<td colspan="1" rowspan="1" valign="top">Thiamine (50–100 mg/day) (<xref ref-type="bibr" rid="B77">77</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Biotin–thiamine-responsive basal ganglia disease</td>
<td colspan="1" rowspan="1" valign="top">SLC19A3</td>
<td colspan="1" rowspan="1" valign="top">THTR2</td>
<td colspan="1" rowspan="1" valign="top">Birth to adolescence</td>
<td colspan="1" rowspan="1" valign="top">Episodic encephalopathy associated with febrile illness, seizures, external ophthalmoplegia, dysphagia, gait ataxia, bilateral lesions of the basal ganglia</td>
<td colspan="1" rowspan="1" valign="top">– Biotin (5–10 mg/kg/day), thiamine (300–900 mg) (<xref ref-type="bibr" rid="B78">78</xref>)<break></break>– Biotin (5–10 mg/kg/day), thiamine (100–200 mg) (<xref ref-type="bibr" rid="B79">79</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Amish lethal microcephaly/THMD3</td>
<td colspan="1" rowspan="1" valign="top">SLC25A19</td>
<td colspan="1" rowspan="1" valign="top">Mitochondrial TPP carrier</td>
<td colspan="1" rowspan="1" valign="top">Birth</td>
<td colspan="1" rowspan="1" valign="top">Episodic encephalopathy associated with lactic acidosis and alpha-ketoglutaric aciduria, microcephaly, delayed psychomotor development, seizures, increased urinary lactate</td>
<td colspan="1" rowspan="1" valign="top">– Phenobarbital (for seizures) and physical therapy (<xref ref-type="bibr" rid="B80">80</xref>)<break></break>– High-fat diet (<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Thiamine metabolism dysfunction syndrome 4/THMD4 (progressive polyneuropathy type)</td>
<td colspan="1" rowspan="1" valign="top">SLC25A19 </td>
<td colspan="1" rowspan="1" valign="top">MTPC</td>
<td colspan="1" rowspan="1" valign="top">Adolescence</td>
<td colspan="1" rowspan="1" valign="top">Episodic encephalopathy associated with febrile illness, transient neurologic dysfunction, residual weakness, progressive axonal polyneuropathy, bilateral striatal degeneration </td>
<td colspan="1" rowspan="1" valign="top">High-dose thiamine administered at the time of the study. Outcome not available (<xref ref-type="bibr" rid="B82">82</xref>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type) THMD5</td>
<td colspan="1" rowspan="1" valign="top">TPK1</td>
<td colspan="1" rowspan="1" valign="top">Thiamine phosphokinase 1</td>
<td colspan="1" rowspan="1" valign="top">Early childhood</td>
<td colspan="1" rowspan="1" valign="top">Episodic encephalopathy (Leigh-like) associated with high serum and CSF lactate with progressive neurologic and motor dysfunctions (gait disturbances, ataxia, dystonia, and spasticity, which, in some cases, may result in loss of ability to walk) triggered by infections. Cognitive function usually preserved; some developmental delay. Some patients may recover from some neurologic deficits; in others, the outcome is fatal.</td>
<td colspan="1" rowspan="1" valign="top">Oral thiamine (100–200; 500 mg/day) (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Carriers of homozygous or compound heterozygous loss-of-function or missense mutations in <italic>SLC19A2</italic> develop a rare condition known as thiamine-responsive megaloblastic anemia (TRMA) or Rogers syndrome (OMIM 249270). Most cases are currently found in isolated populations with consanguineous partners (<xref ref-type="bibr" rid="B85">85</xref>). This early-onset, autosomal recessive disorder is characterized by megaloblastic anemia, macrocytosis, diabetes mellitus, and sensorineural deafness. Other, more variable features include optic atrophy, congenital heart defects, short stature, and significant neurological deficits such as stroke and epilepsy during infancy (<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B86">86</xref>). The term “thiamine-responsive” refers to the observation of clinical, symptomatic improvement after administration of high doses of thiamine (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>).</p>
<p>The biotin–thiamine-responsive basal ganglia disease (BTBGD; OMIM: 607483) is a neurometabolic autosomal recessive disorder caused by a mutation in the <italic>SLC19A3</italic> gene, characterized by subacute encephalopathy with confusion, convulsions, muscle rigidity, ataxia, dysarthria, and dystonia, which can be fatal if left untreated. However, the disorder is completely reversible within by early treatment with biotin (5–10 mg/kg/day) in combination with thiamine [from 100–200 mg (<xref ref-type="bibr" rid="B79">79</xref>) to 300–900 mg (<xref ref-type="bibr" rid="B78">78</xref>); <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>], underscoring the critical nature of a timely diagnosis. Signs and symptoms usually appear during childhood (between the ages of 3 and 10 years), although onset of the disease can vary between newborn period and adulthood (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B88">88</xref>).</p>
<p>The Amish lethal microcephaly (MCPHA; OMIM 607196), also known as thiamine metabolism dysfunction syndrome-3 (THMD3; <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>) (<xref ref-type="bibr" rid="B56">56</xref>), is caused by homozygous mutation in the <italic>SLC25A19</italic> gene. Amish type microcephaly is a severe autosomal recessive metabolic disorder characterized by severe microcephaly apparent at birth, profoundly delayed psychomotor development, brain malformations, and episodic encephalopathy associated with lactic acidosis and α-ketoglutaric aciduria (<xref ref-type="bibr" rid="B89">89</xref>). The clinical management is achieved by administering a high-fat diet (<xref ref-type="bibr" rid="B81">81</xref>), which sustains the production of ATP by mitochondria primarily through fatty acid β-oxidation, bypassing PDH to directly enter the Krebs cycle. Importantly, the metabolic similarity of MCPHA to PDH deficiency (OMIM 312070) indicates the relevance of administering a low-carbohydrate diet to patients with MCPHA to avoid a risk of exacerbating the lactic acidemia.</p>
<p>A less severe variant of the disease, thiamine metabolism dysfunction syndrome 4 (THMD4; OMIM 613710), is similarly caused by a homozygous mutation in the <italic>SLC25A19</italic> gene (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). In THMD4, mitochondrial TPP uptake is reduced but not completely abolished. The disorder is characterized by childhood onset of episodic encephalopathy, causing transient neurologic dysfunction and a slight increase in cerebrospinal fluid (CSF) lactate levels during the acute phase of the disease. Most patients fully recover without therapeutic intervention; however, in some instances, mild residual weakness may persist (<xref ref-type="bibr" rid="B82">82</xref>).</p>
<p>Genetic defects in TPK1 (also known as THMD5) prevent the phosphorylation of thiamine to TPP, the active cofactor. It usually presents during childhood with acute encephalopathic episodes associated with increased serum and CSF lactate. These episodes result in progressive motor dysfunction (e.g., gait defects, ataxia, dystonia, and spasticity) associated with striatal, basal ganglial, and cerebellar regions of the brain, but cognition appeared to remain intact. Given that the phenotype is highly variable, it is likely that residual TPK1 activity and/or other cellular kinases (albeit at a lower extent and favored by the mass action of high thiamine doses) may also phosphorylate thiamine, thereby partly circumventing the metabolic block. This is based on the fact that i) some affected subjects improved with thiamine treatment [100–200 mg/day or 200 mg/twice daily (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>)] or with supplementation with thiamine and niacin, biotin, α-lipoic acid, and ketogenic diet (<xref ref-type="bibr" rid="B90">90</xref>), whereas others did not (<xref ref-type="bibr" rid="B83">83</xref>); and ii) deficiencies in other TPP-dependent enzymes, TKT and BCKADH, have not been observed in subjects with pathogenic mutations in TPK1 (<xref ref-type="bibr" rid="B83">83</xref>).</p>
</sec>
<sec id="s5">
<title>Pathology of Thiamine Deficiency</title>
<p>As indicated above, the pathology of thiamine deficiency entails impaired energy-production from mitochondria in the form of ATP when using pyruvate-generating substrates (e.g., glucose) as well as increased oxidative stress (<xref ref-type="bibr" rid="B27">27</xref>). Under these conditions, glucose <italic>via</italic> glycolysis generates pyruvate, which cannot enter the Krebs cycle as acetyl-CoA due to the low activity of PDH. As such, pyruvate is transaminated to Ala or reduced to lactate <italic>via</italic> lactate dehydrogenase. This is consistent with the elevated lactate and organic acids observed in CSF, urine, and blood during thiamine deficiency (<xref ref-type="bibr" rid="B92">92</xref>–<xref ref-type="bibr" rid="B94">94</xref>).</p>
<p>Thiamine deficiency has been show to stabilize HIF-1α under normoxic conditions, thereby upregulating the expression of the glucose transporter GLUT1, VEGF, aldolase A, LDH, and THTR2 (<xref ref-type="bibr" rid="B95">95</xref>). This stabilization might be achieved by the inhibition of prolyl hydroxylase by increased oxidative stress conditions originated from the lower TKT activity within the PPP. These changes may be accompanied by increased glycolysis and fatty acid oxidation to sustain the cellular energy needs. The latter process may ensue with the ultimate formation of acetyl-CoA, skipping the PDH-catalyzed step. The increased flux of acetyl-CoA will then build up the levels of Krebs’ intermediates including fumarate and succinate (also inhibitors of prolyl hydroxylase), especially if the biotin-dependent pyruvate carboxylase cannot sustain the production of oxaloacetate, the most limiting substrate of the cycle. This also provides a biochemical explanation for the efficacy of the biotin and thiamine supplementation in the treatment of the biotin–thiamine-responsive basal ganglia disease. Although lower thiamine deficiency also affects α-KGDH activity, which is essential to maintain the levels of Glu, Asp, and GABA, its activity seems to be less affected than PDC, thus providing an operational Krebs cycle albeit at a lower efficiency. The lower activity of BCKADH can explain the higher levels of BCAA (Leu, Ile, and Val) in human fluids.</p>
<p>The human central nervous system has a high-energy demand, with 2% of the body mass overseeing about 20% of the total metabolic expenditure, the majority of which is spent on firing action potentials, on neuron communication, through chemical synapses, axon growth, and myelination (<xref ref-type="bibr" rid="B96">96</xref>). With glucose being the primary fuel for energy production in the brain, it is not surprising that mitochondrial dysfunction and the consequent impaired glucose metabolism have been associated with several neurological and neurodevelopmental conditions (<xref ref-type="bibr" rid="B97">97</xref>) and major psychiatric illnesses, such as depression (<xref ref-type="bibr" rid="B98">98</xref>) and schizophrenia (<xref ref-type="bibr" rid="B99">99</xref>). The neurological symptoms in thiamine deficiency are similar to defects of PDH, which most frequently present as Leigh-like syndrome with basal ganglia involvement. Therefore, the nervous system, which is highly specialized in the use of glucose for energy generation, seems to be most vulnerable to PDHC deficiency due to TPP depletion. In the brain, the lower mitochondrial ATP production will limit the maintenance of membrane potential <italic>via</italic> the action of the Na<sup>+</sup>,K<sup>+</sup>-ATPase, thereby compromising nerve conduction and chemical synapses. Moreover, the increased oxidative stress due to the lower TKT activity will damage critical biomolecules, initiating lipid peroxidation and oxidative damage to proteins resulting in fragmentation, posttranslational modifications, and cross-linkings. The modification of epitopes on normal, endogenous molecules may result in the activation of the microglia and immune cells, compounding oxidative stress-mediated damage. The lower TKT has additional detrimental actions: by providing a suboptimal NADPH supply, biosynthetic reactions (nucleic acids and lipids) are undermined. This will limit not only cell proliferation but also the synthesis of fatty acids critical for the myelin sheath of axons. Thus, the combination of increased lipid peroxidation and the decreased fatty acid synthesis can result in demyelination, explaining some of the neurological issues caused by thiamine deficiency.</p>
<p>Altered thiamine metabolism has also been linked to growth of both neuronal soma and dendritic arbors in murine hippocampal neurons in culture. The individual silencing of TPK1 or each of the TPP carriers Slc25a19 and Slc19a3 in neurons significantly decreased dendrite arborization and soma size compared to controls (<xref ref-type="bibr" rid="B100">100</xref>). Conversely, overexpression of TPK1, Slc25a19, and Slc19a3 significantly reversed these changes, leading to increased dendritic branch length and number as well as soma size. Notably, these pathways are independent and nonredundant, as the overexpression of any of the proteins did not improve the dendritic damage caused by suppression of the other two. These findings are indicative of the crucial role that thiamine metabolism plays in soma and dendrite growth (<xref ref-type="bibr" rid="B100">100</xref>), and they are consistent with the microcephaly and neuronal damage reported in cases of thiamine deficiency.</p>
<sec id="s5_1">
<title>In Adults</title>
<sec id="s5_1_1">
<title>Symptoms and Consequences of Thiamine Deficiency</title>
<p>Thiamine deficiency can present with a broad range of neurological signs in children, such as anorexia, irritability, agitation, muscle pain, diminished or abolished deep tendon reflexes, ataxia, paralysis, and a progressively altered level of consciousness. Lactic acidosis may explain some of the generalized symptoms, including lethargy, irritability, anorexia, tachycardia, and tachypnea. These clinical manifestations are probably secondary to mitochondrial dysfunction in the heart and smooth muscle (particularly the gastrointestinal tract) and an autonomic nervous system insult (neurotransmitters). Others such as mood changes (agitation, confusion, and generalized malaise) may result from brain energy deficits as well as from a compromised synthesis of neurotransmitters (glutamate and GABA). Given the above-described varied clinical presentations, especially in children, any unexplained severe neurological signs or symptoms should raise the suspicion of thiamine deficiency [see Hiffler et al. (<xref ref-type="bibr" rid="B3">3</xref>) and references therein].</p>
<p>Generally, in blood from healthy adults, TPP levels &lt;70 nmol/L are suggestive of thiamine deficiency [reference values: 70–180 nmol/L; <uri xlink:href="https://www.mayocliniclabs.com/" xlink:type="simple">https://www.mayocliniclabs.com</uri> (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>)]. Thiamine levels have also been assessed in CSF, in the context of Alzheimer’s disease and in instances of <italic>SLC19A3</italic> mutations (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>). Although no universally accepted reference values exist for CSF, thiamine levels of 5–7 nM are considered normal in adults (<xref ref-type="bibr" rid="B105">105</xref>).</p>
<p>Blood and CSF thiamine levels provide limited information when assessing the thiamine status of a subject, as they not necessarily reflect thiamine metabolic function (<xref ref-type="bibr" rid="B102">102</xref>) or a direct association to its levels in the tissues. As such, assessments of erythrocytes’ TKT and, if available, that of other tissue-specific TPP-dependent enzymes (PDH, αKGDH) are considered gold standards (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Basic TKT activity is usually expressed as units per gram of hemoglobin (g Hb), but more importantly, the percentage of activation of TKT to TPP supplementation are calculated (with 0–15% considered normal). One study reported that the HPLC detection of TPP in whole blood or red blood cells is equally effective to the TKT activation ratio at determining thiamine deficiency (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>The TKT activation ratio (red blood cells) and/or the activities of TPP-dependent enzymes (leukocytes, skin fibroblasts, and muscle biopsies) are usually accompanied by testing the levels of serum lactate and pyruvate, BCAAs, organic acids, as well as brain imaging. The only cases in which the evaluation of free thiamine in plasma/serum and CSF seems to provide a valuable diagnostic tool is when dealing with pathogenic mutations in SLC19A3 (<xref ref-type="bibr" rid="B104">104</xref>). Similarly, urinary excretion of thiamine is also not a reliable method for the assessment of its bodily levels as it is dependent on its intake and absorption. Generally, it is expressed per unit of creatinine to account for renal function, and age should be taken into account as normal values differ in children [120 nmol/mmol creatinine in 1–13 years old (<xref ref-type="bibr" rid="B105">105</xref>)] and adults [220 nmol/mmol creatinine in &gt;18 years old (<xref ref-type="bibr" rid="B105">105</xref>)].</p>
<p>Unfortunately, early symptoms of thiamine deficiency are not pronounced or distinctive enough to warrant a direct diagnosis. They include loss of appetite, nausea, weakness, apathy, fatigue, irritation, sleep disturbances, anorexia, and abdominal discomfort (<xref ref-type="bibr" rid="B106">106</xref>). Furthermore, the identification of specific clinical symptoms of thiamine deficiency is problematic because it is obscured by the contribution of other confounding conditions (comorbidities) such as infections and/or multiple nutritional deficiencies.</p>
<p>The clinical classification of thiamine deficiency falls usually into dry (or neuritic, characterized by polyneuropathy, reduced knee jerk and other tendon reflexes, and progressive severe weakness of muscles) and wet (or cardiac, characterized by edema of the legs, trunk, and face; high cardiac output; ventricular failure; and pulmonary congestion). This classification is based on the amount of fluid that accumulates in the body due to factors like cardiac function and kidney lesions, among others (<xref ref-type="bibr" rid="B107">107</xref>). However, many cases of thiamine deficiency are amply systemic and encompass the nervous and cardiovascular system, as well as the gastrointestinal tract (with symptoms spanning from anorexia, abdominal pain, and constipation) (<xref ref-type="bibr" rid="B108">108</xref>). Long-term consequences of severe thiamine deficiency are manifested by the appearance of hemorrhagic and/or necrotic lesions with neuronal and dendritic spine loss in the thalamus, hypothalamus, and cerebellum (<xref ref-type="bibr" rid="B109">109</xref>–<xref ref-type="bibr" rid="B111">111</xref>), as well as polyneuritis, peripheral edema, cardiac enlargement, and ophthalmoplegia (<xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>When early, generalized thiamine deficiency is suspected, prompt administration of thiamine is advised and typically an effective treatment. A wide range of therapeutic approaches and thiamine doses are reported in the literature, spanning from 1.5 to 600 mg/day (<xref ref-type="bibr" rid="B112">112</xref>), with 10–20 mg/day as divided doses for several weeks for mild polyneuropathy and 20–30 mg/day for moderate to severe, usually until after disappearance of symptoms (<xref ref-type="bibr" rid="B106">106</xref>). Generally, thiamine deficiency is approached with doses of 5–30 mg/day intravenously (IV) or intramuscularly (IM), three times daily, followed by 5–30 mg/day orally until after disappearance of symptoms (<xref ref-type="bibr" rid="B112">112</xref>). However, this approach is notably less effective for individuals with chronic forms of thiamine deficiency-related disorders involving encephalopathies (see the section Wernicke Encephalopathy) (<xref ref-type="bibr" rid="B113">113</xref>) or TPK1 deficiencies. In the latter case, it would be worth to explore a treatment directly with TPP; however, it is not clear whether this phosphorylated thiamine form would cross the blood–brain barrier and/or reach subcellular targets such as PDH.</p>
</sec>
<sec id="s5_1_2">
<title>Wernicke Encephalopathy</title>
<p>Wernicke encephalopathy (WE) is a thiamine-deficiency-related acute neuropsychiatric condition, often associated with alcohol abuse (<xref ref-type="bibr" rid="B114">114</xref>). It is characterized by ataxia, loss of muscle coordination, memory loss, confusion, and ocular abnormalities (ophthalmoplegia). Failure to timely diagnose the disease and the lack of an appropriate therapy result in death in 17% of the cases, while 84% will undergo permanent brain damage involving severe short-term memory loss and hallucinations [or Korsakoff’s syndrome (KS)], residual syndrome in patients previously affected with WE (<xref ref-type="bibr" rid="B115">115</xref>). Because of the close association between these two conditions, they often get referred to as Wernicke–Korsakoff syndrome (WKS). Recently, it has been suggested that WE may be underdiagnosed (<xref ref-type="bibr" rid="B116">116</xref>), with similar incidence in both adults and children (<xref ref-type="bibr" rid="B117">117</xref>), with ratification of the diagnosis in 0.4–2.8% of <italic>postmortem</italic> cases, but recognized only in 32% and 6% of patients with and without alcoholism, respectively. In particular, it would be critical to consider WE in any patient showing two of the following characteristics: nutritional deficiency, cerebellar or oculomotor abnormalities, or impaired mental state or memory (<xref ref-type="bibr" rid="B116">116</xref>). Only 16% of the WE cases are expected to fully recover after thiamine supplementation. As oral absorption is highly variable and patient-dependent (<xref ref-type="bibr" rid="B116">116</xref>), parenteral treatment is highly recommended with daily doses of 100–200 mg thiamine (IV) for non-alcoholics and 500 mg (up to three administrations daily) for alcoholics (<xref ref-type="bibr" rid="B114">114</xref>).</p>
<p>A substantial body of literature has been published in the past &gt;50 years regarding WE. A detailed description of the clinical features, pathophysiology, and treatment of this syndrome is beyond the scope of this review.</p>
</sec>
<sec id="s5_1_3">
<title>Depression</title>
<p>A number of studies have shown an inverse association between thiamine levels and symptoms of depression in adults. A cross-sectional study on &gt;1,500 elderly Chinese (age 50–70 years) showed that subjects with lower levels of erythrocyte thiamine (likely representing TPP bound to TKT) displayed more severe symptoms of depression (<xref ref-type="bibr" rid="B118">118</xref>). In this report, although no apparent differences were noted between individuals with and without depressive symptoms in dietary thiamine intake, the authors could not exclude errors in dietary assessment related to differences in food processing (<xref ref-type="bibr" rid="B118">118</xref>). In addition, other factors like diabetes, altered hormone profiles, and increased alcohol consumption observed in some individuals with depressive symptoms could play a critical role in the bioavailability of thiamine (<xref ref-type="bibr" rid="B118">118</xref>).</p>
<p>A direct correlation between thiamine deficiency and symptoms of major depressive disorder (MDD) had been previously found in a population of 74 individuals with history of malnutrition (<xref ref-type="bibr" rid="B119">119</xref>). These findings were confirmed by another study involving 118 geriatric patients (<xref ref-type="bibr" rid="B120">120</xref>), although in this particular instance, no information about dietary thiamine intake was provided.</p>
<p>Additionally, Ghaleiha and colleagues explored the interventional effect of thiamine supplementation in thiamine-deficient subjects with MDD in a 12-week, randomized, double-blind clinical trial (<xref ref-type="bibr" rid="B121">121</xref>). The study concluded that symptoms of depression improved significantly in subjects with MDD following 6 weeks of thiamine supplementation compared to placebo.</p>
<p>Finally, positive mood changes (clearheadedness, increased energy and appetite, improved sleep patterns, and decreased fatigue) have been observed following thiamine supplementation in healthy elderly (<xref ref-type="bibr" rid="B16">16</xref>) as well as younger (<xref ref-type="bibr" rid="B122">122</xref>) women, compared to the same population assigned to the placebo group. Interestingly, while in the elderly population, a marginal deficiency of thiamine was reportedly due to the lack of a national thiamine enrichment policy for grains and cereals at the time of the study, in the case of younger women, a normal thiamine intake was recorded for all participants at baseline.</p>
</sec>
</sec>
<sec id="s5_2">
<title>In Children</title>
<p>In children, thiamine deficiency presents with acute symptoms and very rapid onset, and in the vast majority of cases, it affect infants who are breast-fed by thiamine-deficient mothers or with thiamine-deficient formulas.</p>
<p>A pivotal study that highlighted the crucial role of thiamine as an essential nutrient for infant development and discussed how TD phenotype may be confused or overlooked with other diseases was based on an epidemiological investigation on 24- to 39-month-old children presenting repeated vomiting, irritability, and lethargy, without major neurological abnormalities. All children who had consumed the same soy-based, thiamine-deficient formula (&lt;0.5 mg/g formula) suffered from language and motor development deficits compared to sex- and age-matched children fed with other milk-based diets (<xref ref-type="bibr" rid="B123">123</xref>). Another study on the acute and long-term effects of thiamine-deficient formula-fed children who were not promptly diagnosed reported that a subset of patients (36%) died of cardiac and respiratory complications (<xref ref-type="bibr" rid="B124">124</xref>), and the remaining children developed intellectual disabilities, neurodevelopmental delay, and major motor dysfunction by the age of 9 (<xref ref-type="bibr" rid="B124">124</xref>). Recently, in another study by Harel et al. (<xref ref-type="bibr" rid="B125">125</xref>), more than 50% of a preschool children cohort, who were exposed to a thiamine-deficient diet for more than 1 month during the first 24 months of life, developed movement and motor skills difficulties compared to less than 10% among children with appropriate thiamine intake.</p>
<sec id="s5_2_1">
<title>Infantile Thiamine Deficiency</title>
<p>Infantile thiamine deficiency (ITD) manifests after 2–3 weeks of thiamine deprivation with initially milder symptoms (refusal to eat, vomiting, and irritability), followed by rapid deterioration, with a high fatality rate (<xref ref-type="bibr" rid="B106">106</xref>). Newborns who are severely thiamine deprived may develop infantile beriberi. The disorder is rare in developed countries, as it can be readily treated with thiamine supplementation (<xref ref-type="bibr" rid="B126">126</xref>). However, it remains a concern in developing countries among infants breast-fed by thiamine-deficient mothers or fed with thiamine-deficient formula. Without proper thiamine supplementation, the deficiency is characterized by a rapid onset of symptoms involving vomiting, diarrhea, tachypnea, convulsions, ataxia, paralysis, cardiac dysfunction, and heart failure. In many cases, fatality occurs quickly (<xref ref-type="bibr" rid="B127">127</xref>). Those children who survive thiamine-deficiency-related WE [see the section Wernicke Encephalopathy and Vasconcelos et al. (<xref ref-type="bibr" rid="B128">128</xref>)] continue to live with developmental disabilities including severe epilepsy, language impairment, loss of motor function (to varying degrees), and mental retardation (mild to profound) (<xref ref-type="bibr" rid="B124">124</xref>).</p>
<p>In two separate case reports, one newborn (2 months old) with early infantile Leigh-like <italic>SLC19A3</italic> gene defect (<xref ref-type="bibr" rid="B129">129</xref>) and one (30 days old) with THTR2 deficiency (<xref ref-type="bibr" rid="B130">130</xref>) responded dramatically differently to thiamine supplementation. In the first case, the 2-month-old infant initially presenting with fever, feeding difficulties, and complex partial seizures (<xref ref-type="bibr" rid="B129">129</xref>) subsequently developed a severe encephalopathy. MRI showed abnormalities in both cerebral hemispheres as well as in brainstem and cerebellum, basal ganglia, and thalamus. A diffuse volume loss was also noted in both hemispheres. At the biochemical level, metabolic acidosis was diagnosed. Despite a prompt therapeutic regimen consisting of thiamine (37.5 mg/kg) and biotin (10 mg/kg) twice daily, the patient’s conditions never improved and he died at 4 months of age. The lack of response to treatment in this instance seems to suggest that its effectiveness is completely halted in the presence of a null mutation leading to a complete loss of function of the thiamine transporter in the early-onset form [see Table 1 in Alfadhel (<xref ref-type="bibr" rid="B129">129</xref>)].</p>
<p>In the second case report, the infant showed acute mitochondrial encephalopathy, accompanied by increased level of lactate in the blood and cerebrospinal fluid as well as abnormal levels of α-ketoglutarate in the urine. Cortico-subcortical lesions were visualized by MRI, some of which seemed to have appeared in the perinatal period (<xref ref-type="bibr" rid="B130">130</xref>). Within 48 h after administration of thiamine (100 mg/day), biotin (10 mg/day), and carnitine (300 mg/day), a remarkable improvement was observed in both clinical and biochemical outcomes (<xref ref-type="bibr" rid="B130">130</xref>). After discontinuing biotin, the patient remained stable for 6 months on thiamine supplementation (20 mg/kg/day) (<xref ref-type="bibr" rid="B130">130</xref>).</p>
<p>It is now widely established that less severe cases of ITD can be treated (to varying degrees) with early thiamine supplementation. In general, therapeutic recommended doses are 10–25 mg/daily IV or IM for 2 weeks, or 10–50 mg/daily orally, followed by 5–10 mg/daily for 1 month (<xref ref-type="bibr" rid="B112">112</xref>).</p>
</sec>
<sec id="s5_2_2">
<title>Autism Spectrum Disorders</title>
<p>More recently, thiamine-based treatments have gained a great deal of attention as a therapeutic strategy for other developmental and neurological disorders linked to mitochondrial dysfunction. One such disorder is autism spectrum disorder (ASD), a group of complex neurological and developmental disabilities, with a prevalence of 1 in 54 and 1 in 252, respectively, for males and females age 8 years in the United States (<xref ref-type="bibr" rid="B131">131</xref>). “Spectrum” refers to the wide heterogeneity and range of symptoms within three characteristic patterns: atypical cognitive profile, executive dysfunction, and unusually restricted or repetitive behavior (<xref ref-type="bibr" rid="B131">131</xref>). Individuals with ASD show severe cognitive and verbal impairments and experience challenges in the development of critical social communication skills.</p>
<p>Limited findings are available on the link between thiamine bioavailability and the development of autism. However, studies show that the consumption of herbal supplements rich in thiaminase during pregnancy (<xref ref-type="bibr" rid="B132">132</xref>) or alcohol exposure <italic>in utero</italic> (<xref ref-type="bibr" rid="B133">133</xref>) may predispose a fetus to thiamine deficiency during pregnancy and increased risk for ASD. A study conducted on rat pups nursed by thiamine-deficient dams displayed comparable findings, in which the offspring exhibited behavioral abnormalities consistent with ASD symptoms (<xref ref-type="bibr" rid="B134">134</xref>).</p>
<p>A number of hypotheses have been put forward on the pathophysiological mechanisms linking thiamine deficiency and ASD (<xref ref-type="bibr" rid="B135">135</xref>), including i) increased apoptosis, due to the link of thiamine with p53 (<xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B137">137</xref>), Bcl-2 (<xref ref-type="bibr" rid="B138">138</xref>, <xref ref-type="bibr" rid="B139">139</xref>), and caspases (<xref ref-type="bibr" rid="B140">140</xref>); ii) deregulation of the serotoninergic system (<xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B142">142</xref>); and iii) increased oxidative stress, due to the putative role of thiamine in prostaglandin expression, decreased lipid peroxidation as well as expression of nitric oxide synthase (<xref ref-type="bibr" rid="B143">143</xref>, <xref ref-type="bibr" rid="B144">144</xref>), and its involvement as a cofactor for TKT in the PPP, master regulator of NADPH homeostasis.</p>
<p>More interestingly, a subset of children with ASD has been characterized by PDH deficiency and mitochondrial dysfunction (<xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B146">146</xref>), suggesting that thiamine deficiency may also ensue in PDH deficits or that a borderline thiamine intake would compound the preexistent PDH deficit, precipitating energy metabolism and leading to ASD in genetically predisposed individuals. Furthermore, a more recent study has shown decreased TPP levels in plasma from ASD children compared to healthy controls (<xref ref-type="bibr" rid="B147">147</xref>), suggesting either lower consumption or an impaired absorption from the gastrointestinal tract, providing a link between thiamine metabolism and the gut microbiome, which has been considered in the context of ASD (<xref ref-type="bibr" rid="B148">148</xref>). While there is no evidence to suggest that a sole deficiency in thiamine may result in ASD, it could certainly be a contributing element in concert with other epigenetic factors in the presence of an already predisposed genetic background.</p>
<p>Based on the finding that children with ASD seem to have an impairment in the catabolism and excretion of thiol-containing heavy metals, Lonsdale et al. proposed that thiamine supplementation may be indicated for all children with ASD (<xref ref-type="bibr" rid="B149">149</xref>), with the idea that heavy metal toxicity can hamper TKT activity, increase oxidative stress, and, in turn, disrupt thiamine homeostasis. Hence, thiamine supplementation may, to some extent, improve carbohydrate metabolism, mitochondrial function, and brain energy production (<xref ref-type="bibr" rid="B150">150</xref>). In that study, children with ASD were administered a thiamine derivative, bi-daily for 2 months and noted improved communication skills, sociability, sensory/cognitive awareness, and behavior in 8 out of the 10 children studied as well as reduction in urine arsenic and mercury levels (<xref ref-type="bibr" rid="B149">149</xref>). In a separate, double-blind, placebo-controlled study, researchers noted decreased oxidative stress, increased ATP in plasma and NADH and NADPH production in red blood cells, and improved PGI-R (Parent Global Impressions—Revised) scores in hyperactivity, tantrum, and receptive language categories in autistic children administered vitamin/mineral supplementation, which included thiamine, over a 3-month period (<xref ref-type="bibr" rid="B151">151</xref>).</p>
<p>These pilot studies provide some support for a thiamine-based approach as a therapeutic intervention for ASD. However, further studies are warranted to clarify the role and specificity of thiamine supplementation for the management of the diverse and extensive range of ASD features.</p>
</sec>
<sec id="s5_2_3">
<title>Depression in Children and Child-Bearing Women</title>
<p>To our knowledge, to date, only one study has investigated the contribution of thiamine levels to pediatric depression (<xref ref-type="bibr" rid="B152">152</xref>). Surprisingly, and opposite to findings in adults, this study found a direct correlation between thiamine intake and depressive symptoms in Spanish schoolchildren (7–9 years old).</p>
<p>Although a fairly common condition among teenagers, little is known about depression and its treatment in children 12 years old and younger (<xref ref-type="bibr" rid="B153">153</xref>). Depression in children is often overlooked and oftentimes mistaken by teachers and parents and labeled as laziness, learning disabilities, or belligerence (<xref ref-type="bibr" rid="B154">154</xref>). Similarly, the “acting out” behavior observed in pediatric depression is often labeled as bullying, rebellion, or even psychotic behavior (<xref ref-type="bibr" rid="B154">154</xref>).</p>
<p>The effects of thiamine supplementation might be significant as palliative treatment in postpartum depression (PPD) and have a critical role on the infant’s subsequent cognitive development. PPD has been associated with an increased risk of developing learning disabilities, Attention-Deficit/Hyperactivity Disorder (ADHD), and anxiety disorders in toddlers, which makes PPD a critical concern for both mother and infant (<xref ref-type="bibr" rid="B155">155</xref>). Nikseresht et al. investigated the therapeutic effects of Zn<sup>2+</sup>, Mg<sup>2+</sup>, and TPP supplementation in a PPD mouse model. Improvements in depressive symptoms and anxiety-like behaviors (tested by forced swimming test and elevated plus-maze), as well as total antioxidant capacity, were noted in the dams when the nutrients were administered on postpartum day 3 (<xref ref-type="bibr" rid="B156">156</xref>). Taken together, these findings indicate that thiamine supplementation may be a promising therapeutic strategy for PPD. However, future studies should address the role of thiamine in PPD independently and whether supplementation in instances of PPD positively impacts infant development.</p>
</sec>
</sec>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusions and Future Perspectives</title>
<p>Thiamine deficiency, regardless of the underlying mechanism (genetic or epigenetic), impairs critical TPP-dependent enzymes involved in intermediary metabolism and antioxidant defenses. The consequent decrease in ATP production and increased oxidative stress result in neurological deficits, which become especially detrimental during critical windows of neurodevelopment. In the recent years, thiamine supplementation has been contemplated, with some success, as a therapeutic approach for neurodevelopmental disorders, including ASD and major psychiatric disorders (i.e., depression). However, the vast heterogeneity of the pathogenic mechanisms underlying these conditions, along with the difficulty of diagnosis and the assumption that diets from developed countries supply enough thiamine to match the caloric intake (including perinatal periods), has not prompted enough research to address the role and effects of thiamine supplementation as a therapeutic strategy in the context of neurodevelopment/neurodegeneration. Of note, and an often overlooked issue, is the lack of incorporation of antioxidants into supplemental treatments that are deemed critical to minimize the thiamine-deficiency-dependent oxidative-stress-derived damage. This will also allow to shed light on the contribution of oxidative stress versus mitochondrial dysfunction to the morbidity of neurodegenerative disorders.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>SD and MT equally contributed to the writing of the manuscript. EN contributed to writing and edited the text. CG conceptualized the paper, contributed to writing, and edited the text.</p>
</sec>
<sec id="s8">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank the technical assistance of Dr. E. Penna.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>PR</given-names></name><name><surname>Singleton</surname><given-names>CK</given-names></name><name><surname>Hiller-Sturmhofel</surname><given-names>S</given-names></name></person-group>
<article-title>The role of thiamine deficiency in alcoholic brain disease</article-title>. <source/>Alcohol Res Health (<year>2003</year>) <volume>27</volume>:<page-range>134–42</page-range>. </mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Martel</surname><given-names>JL</given-names></name><name><surname>Franklin</surname><given-names>DS</given-names></name></person-group>
<article-title>Vitamin B1 (thiamine)</article-title>. In: <source/>StatPearls. <publisher-loc>Treasure Island (FL)</publisher-loc>, (<year>2018</year>).</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hiffler</surname><given-names>L</given-names></name><name><surname>Rakotoambinina</surname><given-names>B</given-names></name><name><surname>Lafferty</surname><given-names>N</given-names></name><name><surname>Martinez Garcia</surname><given-names>D</given-names></name></person-group>
<article-title>Thiamine deficiency in tropical pediatrics: new insights into a neglected but vital metabolic challenge</article-title>. <source/>Front Nutr (<year>2016</year>) <volume>3</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2016.00016</pub-id>
<pub-id pub-id-type="pmid">27379239</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singleton</surname><given-names>CK</given-names></name><name><surname>Martin</surname><given-names>PR</given-names></name></person-group>
<article-title>Molecular mechanisms of thiamine utilization</article-title>. <source/>Curr Mol Med (<year>2001</year>) <volume>1</volume>:<fpage>197</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.2174/1566524013363870</pub-id>
<pub-id pub-id-type="pmid">11899071</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Said</surname><given-names>HM</given-names></name><name><surname>Nexo</surname><given-names>E</given-names></name></person-group>
<article-title>Chapter 64—Mechanisms and regulation of intestinal absorption of water-soluble vitamins: cellular and molecular aspects</article-title>. In: <person-group person-group-type="editor"><name><surname>Johnson</surname><given-names>LR</given-names></name><name><surname>Ghishan</surname><given-names>FK</given-names></name><name><surname>Kaunitz</surname><given-names>JD</given-names></name><name><surname>Merchant</surname><given-names>JL</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name><name><surname>Wood</surname><given-names>JD</given-names></name></person-group>, editors. <source/>Physiology of the gastrointestinal tract, <edition>5th ed</edition>
<publisher-loc>Boston</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2012</year>). p. <page-range>1711–56</page-range>. <pub-id pub-id-type="doi">10.1016/B978-0-12-382026-6.00064-6</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Calhau</surname><given-names>C</given-names></name><name><surname>Faria</surname><given-names>A</given-names></name><name><surname>Keating</surname><given-names>E</given-names></name><name><surname>Martel</surname><given-names>F</given-names></name></person-group>
<article-title>Chapter 39—Interaction of polyphenols with the intestinal and placental absorption of some nutrients and other compounds</article-title>. In: <person-group person-group-type="editor"><name><surname>Watson</surname><given-names>RR</given-names></name><name><surname>Preedy</surname><given-names>VR</given-names></name><name><surname>Zibadi</surname><given-names>S</given-names></name></person-group>, editors. <source/>Polyphenols in human health and disease. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2014</year>). p. <page-range>523–36</page-range>. <pub-id pub-id-type="doi">10.1016/B978-0-12-398456-2.00039-6</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lonsdale</surname><given-names>D</given-names></name></person-group>
<article-title>A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives</article-title>. <source/>Evid Based Complement Alternat Med (<year>2006</year>) <volume>3</volume>:<fpage>49</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1093/ecam/nek009</pub-id>
<pub-id pub-id-type="pmid">16550223</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lonsdale</surname><given-names>D</given-names></name><name><surname>Marrs</surname><given-names>C</given-names></name></person-group>
<article-title>High-calorie malnutrition and its impact on health</article-title>. In: <person-group person-group-type="editor"><name><surname>Lonsdale</surname><given-names>D</given-names></name><name><surname>Marrs</surname><given-names>C</given-names></name></person-group>, editors. <source/>Thiamine deficiency disease, dysautonomia, and high calorie malnutrition. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2017</year>). p. <page-range>213–61</page-range>. <pub-id pub-id-type="doi">10.1016/B978-0-12-810387-6.00006-X</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roust</surname><given-names>LR</given-names></name><name><surname>DiBaise</surname><given-names>JK</given-names></name></person-group>
<article-title>Nutrient deficiencies prior to bariatric surgery</article-title>. <source/>Curr Opin Clin Nutr Metab Care (<year>2017</year>) <volume>20</volume>:<page-range>138–44</page-range>. <pub-id pub-id-type="doi">10.1097/MCO.0000000000000352</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scrimshaw</surname><given-names>NS</given-names></name><name><surname>Behar</surname><given-names>M</given-names></name></person-group>
<article-title>Malnutrition in underdeveloped countries</article-title>. <source/>N Engl J Med (<year>1965</year>) <volume>272</volume>:<page-range>193–98</page-range> CONCL. <pub-id pub-id-type="doi">10.1056/NEJM196501282720406</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitfield</surname><given-names>KC</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Chamnan</surname><given-names>C</given-names></name><name><surname>Karakochuk</surname><given-names>CD</given-names></name><name><surname>Sophonneary</surname><given-names>P</given-names></name><name><surname>Kuong</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>High prevalence of thiamine (vitamin B1) deficiency in early childhood among a nationally representative sample of Cambodian women of childbearing age and their children</article-title>. <source/>PLoS Negl Trop Dis (<year>2017</year>) <volume>11</volume>:<elocation-id>e0005814</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005814</pub-id>
<pub-id pub-id-type="pmid">28873391</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujita</surname><given-names>A</given-names></name></person-group>
<article-title>Thiaminase</article-title>. <source/>Adv Enzymol Relat Subj Biochem (<year>1954</year>) <volume>15</volume>:<fpage>389</fpage>–<lpage>421</lpage>. <pub-id pub-id-type="pmid">13158184</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leichter</surname><given-names>J</given-names></name><name><surname>Joslyn</surname><given-names>MA</given-names></name></person-group>
<article-title>Kinetics of thiamin cleavage by sulphite</article-title>. <source/>Biochem J (<year>1969</year>) <volume>113</volume>:<page-range>611–15</page-range>. <pub-id pub-id-type="doi">10.1042/bj1130611</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hilker</surname><given-names>DM</given-names></name><name><surname>Somogyi</surname><given-names>JC</given-names></name></person-group>
<article-title>Antithiamins of plant origin: their chemical nature and mode of action</article-title>. <source/>Ann N Y Acad Sci (<year>1982</year>) <volume>378</volume>:<page-range>137–45</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1982.tb31192.x</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vimokesant</surname><given-names>S</given-names></name><name><surname>Kunjara</surname><given-names>S</given-names></name><name><surname>Rungruangsak</surname><given-names>K</given-names></name><name><surname>Nakornchai</surname><given-names>S</given-names></name><name><surname>Panijpan</surname><given-names>B</given-names></name></person-group>
<article-title>Beriberi caused by antithiamin factors in food and its prevention</article-title>. <source/>Ann N Y Acad Sci (<year>1982</year>) <volume>378</volume>:<page-range>123–36</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1982.tb31191.x</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smidt</surname><given-names>LJ</given-names></name><name><surname>Cremin</surname><given-names>FM</given-names></name><name><surname>Grivetti</surname><given-names>LE</given-names></name><name><surname>Clifford</surname><given-names>AJ</given-names></name></person-group>
<article-title>Influence of thiamin supplementation on the health and general well-being of an elderly Irish population with marginal thiamin deficiency</article-title>. <source/>J Gerontol (<year>1991</year>) <volume>46</volume>:M<fpage>16</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/geronj/46.1.M16</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thornalley</surname><given-names>PJ</given-names></name><name><surname>Babaei-Jadidi</surname><given-names>R</given-names></name><name><surname>Al Ali</surname><given-names>H</given-names></name><name><surname>Rabbani</surname><given-names>N</given-names></name><name><surname>Antonysunil</surname><given-names>A</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease</article-title>. <source/>Diabetologia (<year>2007</year>) <volume>50</volume>:<page-range>2164–70</page-range>. <pub-id pub-id-type="doi">10.1007/s00125-007-0771-4</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sequeira Lopes da Silva</surname><given-names>JT</given-names></name><name><surname>Almaraz Velarde</surname><given-names>R</given-names></name><name><surname>Olgado Ferrero</surname><given-names>F</given-names></name><name><surname>Robles Marcos</surname><given-names>M</given-names></name><name><surname>Perez Civantos</surname><given-names>D</given-names></name><name><surname>Ramirez Moreno</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Wernicke’s encephalopathy induced by total parental nutrition</article-title>. <source/>Nutr Hosp (<year>2010</year>) <volume>25</volume>:<page-range>1034–36</page-range>. </mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Junior</surname><given-names>EV</given-names></name><name><surname>Cesar</surname><given-names>CL</given-names></name><name><surname>Fisberg</surname><given-names>RM</given-names></name><name><surname>Marchioni</surname><given-names>DM</given-names></name></person-group>
<article-title>Socio-economic variables influence the prevalence of inadequate nutrient intake in Brazilian adolescents: results from a population-based survey</article-title>. <source/>Public Health Nutr (<year>2011</year>) <volume>14</volume>:<page-range>1533–8</page-range>. <pub-id pub-id-type="doi">10.1017/S1368980011000760</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Renthal</surname><given-names>W</given-names></name><name><surname>Marin-Valencia</surname><given-names>I</given-names></name><name><surname>Evans</surname><given-names>PA</given-names></name></person-group>
<article-title>Thiamine deficiency secondary to anorexia nervosa: an uncommon cause of peripheral neuropathy and Wernicke encephalopathy in adolescence</article-title>. <source/>Pediatr Neurol (<year>2014</year>) <volume>51</volume>:<page-range>100–3</page-range>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.03.025</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kerns</surname><given-names>JC</given-names></name><name><surname>Arundel</surname><given-names>C</given-names></name><name><surname>Chawla</surname><given-names>LS</given-names></name></person-group>
<article-title>Thiamin deficiency in people with obesity</article-title>. <source/>Adv Nutr (<year>2015</year>) <volume>6</volume>:<page-range>147–53</page-range>. <pub-id pub-id-type="doi">10.3945/an.114.007526</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandrakumar</surname><given-names>A</given-names></name><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Jong</surname><given-names>GW</given-names></name></person-group>
<article-title>Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis</article-title>. <source/>J Basic Clin Physiol Pharmacol (<year>2018</year>) <volume>30</volume>:<page-range>153–62</page-range>. <pub-id pub-id-type="doi">10.1515/jbcpp-2018-0075</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamasak</surname><given-names>T</given-names></name><name><surname>Kul</surname><given-names>S</given-names></name><name><surname>Tusat</surname><given-names>M</given-names></name><name><surname>Ozgun</surname><given-names>N</given-names></name><name><surname>Cansu</surname><given-names>A</given-names></name></person-group>
<article-title>A case of Wernicke encephalopathy developing after ileal bypass surgery</article-title>. <source/>Pediatr Emerg Care (<year>2018</year>) <volume>34</volume>:<fpage>e223</fpage>–<lpage>e225</lpage>. <pub-id pub-id-type="doi">10.1097/PEC.0000000000001472</pub-id>
<pub-id pub-id-type="pmid">29596284</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Croft</surname><given-names>L</given-names></name><name><surname>Napoli</surname><given-names>E</given-names></name><name><surname>Hung</surname><given-names>CK</given-names></name><name><surname>St Leger</surname><given-names>J</given-names></name><name><surname>Gearhart</surname><given-names>S</given-names></name><name><surname>Heym</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Clinical evaluation and biochemical analyses of thiamine deficiency in Pacific harbor seals (<italic>Phoca vitulina</italic>) maintained at a zoological facility</article-title>. <source/>J Am Vet Med Assoc (<year>2013</year>) <volume>243</volume>:<page-range>1179–89</page-range>. <pub-id pub-id-type="doi">10.2460/javma.243.8.1179</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yee</surname><given-names>SW</given-names></name><name><surname>Giacomini</surname><given-names>KM</given-names></name></person-group>
<article-title>OCT1 in hepatic steatosis and thiamine disposition</article-title>. <source/>Cell Cycle (<year>2015</year>) <volume>14</volume>:<page-range>283–4</page-range>. <pub-id pub-id-type="doi">10.1080/15384101.2015.1006532</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vernau</surname><given-names>K</given-names></name><name><surname>Napoli</surname><given-names>E</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Ross-Inta</surname><given-names>C</given-names></name><name><surname>Cameron</surname><given-names>J</given-names></name><name><surname>Bannasch</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Thiamine deficiency-mediated brain mitochondrial pathology in Alaskan Huskies with mutation in SLC19A3.1</article-title>. <source/>Brain Pathol (<year>2015</year>) <volume>25</volume>:<page-range>441–53</page-range>. <pub-id pub-id-type="doi">10.1111/bpa.12188</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group>
<article-title>Thiamin deficiency and brain disorders</article-title>. <source/>Nutr Res Rev (<year>2003</year>) <volume>16</volume>:<page-range>277–84</page-range>. <pub-id pub-id-type="doi">10.1079/NRR200367</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>J</given-names></name><name><surname>Love</surname><given-names>ER</given-names></name><name><surname>Pratt</surname><given-names>OE</given-names></name></person-group>
<article-title>Kinetics of thiamine transport across the blood–brain barrier in the rat</article-title>. <source/>J Physiol (<year>1982</year>) <volume>327</volume>:<fpage>95</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.1982.sp014222</pub-id>
<pub-id pub-id-type="pmid">7120152</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Comincioli</surname><given-names>V</given-names></name><name><surname>Reggiani</surname><given-names>C</given-names></name><name><surname>Patrini</surname><given-names>C</given-names></name></person-group>
<article-title>Nervous tissue thiamine metabolism <italic>in vivo.</italic> II</article-title>. <source/>Brain Res (<year>1984</year>) <volume>293</volume>:<page-range>329–42</page-range>. <pub-id pub-id-type="doi">10.1016/0006-8993(84)91240-X</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name><name><surname>Giguere</surname><given-names>JF</given-names></name><name><surname>Besnard</surname><given-names>AM</given-names></name></person-group>
<article-title>Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 2</article-title>. <source/>Neurochem Res (<year>1986</year>) <volume>11</volume>:<page-range>567–77</page-range>. <pub-id pub-id-type="doi">10.1007/BF00965326</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bettendorff</surname><given-names>L</given-names></name><name><surname>Wins</surname><given-names>P</given-names></name><name><surname>Lesourd</surname><given-names>M</given-names></name></person-group>
<article-title>Subcellular localization and compartmentation of thiamine derivatives in rat brain</article-title>. <source/>Biochim Biophys Acta (<year>1994</year>) <volume>1222</volume>:<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0167-4889(94)90018-3</pub-id>
<pub-id pub-id-type="pmid">8186256</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bettendorff</surname><given-names>L</given-names></name><name><surname>Mastrogiacomo</surname><given-names>F</given-names></name><name><surname>Kish</surname><given-names>SJ</given-names></name><name><surname>Grisar</surname><given-names>T</given-names></name></person-group>
<article-title>Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain</article-title>. <source/>J Neurochem (<year>1996</year>) <volume>66</volume>:<page-range>250–8</page-range>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.1996.66010250.x</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Laforenza</surname><given-names>U</given-names></name></person-group>
<article-title>Thiamine intestinal transport and related issues: recent aspects</article-title>. <source/>Proc Soc Exp Biol Med (<year>2000</year>) <volume>224</volume>:<page-range>246–55</page-range>. <pub-id pub-id-type="doi">10.1046/j.1525-1373.2000.22428.x</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schaller</surname><given-names>K</given-names></name><name><surname>Holler</surname><given-names>H</given-names></name></person-group>
<article-title>Thiamine absorption in the rat. II. Intestinal alkaline phosphatase activity and thiamine absorption from rat small intestine <italic>in-vitro</italic> and <italic>in-vivo</italic>
</article-title>. <source/>Int J Vitam Nutr Res (<year>1975</year>) <volume>45</volume>:<page-range>30–8</page-range>. </mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nabokina</surname><given-names>SM</given-names></name><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Valle</surname><given-names>JE</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group>
<article-title>Adaptive regulation of human intestinal thiamine uptake by extracellular substrate level: a role for THTR-2 transcriptional regulation</article-title>. <source/>Am J Physiol Gastrointest Liver Physiol (<year>2013</year>) <volume>305</volume>:<page-range>G593–599</page-range>. <pub-id pub-id-type="doi">10.1152/ajpgi.00237.2013</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laforenza</surname><given-names>U</given-names></name><name><surname>Gastaldi</surname><given-names>G</given-names></name><name><surname>Rindi</surname><given-names>G</given-names></name></person-group>
<article-title>Thiamine outflow from the enterocyte: a study using basolateral membrane vesicles from rat small intestine</article-title>. <source/>J Physiol (<year>1993</year>) <volume>468</volume>:<page-range>401–12</page-range>. <pub-id pub-id-type="doi">10.1113/jphysiol.1993.sp019778</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talwar</surname><given-names>D</given-names></name><name><surname>Davidson</surname><given-names>H</given-names></name><name><surname>Cooney</surname><given-names>J</given-names></name><name><surname>St</surname><given-names>JRD</given-names></name></person-group>
<article-title>Vitamin B(1) status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay</article-title>. <source/>Clin Chem (<year>2000</year>) <volume>46</volume>:<page-range>704–10</page-range>. </mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Rekow</surname><given-names>SS</given-names></name><name><surname>Singleton</surname><given-names>CA</given-names></name><name><surname>Sekhon</surname><given-names>HS</given-names></name><name><surname>Dissen</surname><given-names>GA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis</article-title>. <source/>J Neurochem (<year>2013</year>) <volume>126</volume>:<page-range>451–61</page-range>. <pub-id pub-id-type="doi">10.1111/jnc.12298</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>SLC44A4 mutation causes autosomal dominant hereditary postlingual non-syndromic mid-frequency hearing loss</article-title>. <source/>Hum Mol Genet (<year>2017</year>) <volume>26</volume>:<fpage>3234</fpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddx232</pub-id>
<pub-id pub-id-type="pmid">28859437</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nabokina</surname><given-names>SM</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Valle</surname><given-names>JE</given-names></name><name><surname>Yuasa</surname><given-names>H</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group>
<article-title>Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter</article-title>. <source/>J Biol Chem (<year>2017</year>) <volume>292</volume>:<fpage>16526</fpage>. <pub-id pub-id-type="doi">10.1074/jbc.A113.528257</pub-id>
<pub-id pub-id-type="pmid">28986434</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleming</surname><given-names>JC</given-names></name><name><surname>Tartaglini</surname><given-names>E</given-names></name><name><surname>Steinkamp</surname><given-names>MP</given-names></name><name><surname>Schorderet</surname><given-names>DF</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Neufeld</surname><given-names>EJ</given-names></name></person-group>
<article-title>The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter</article-title>. <source/>Nat Genet (<year>1999</year>) <volume>22</volume>:<page-range>305–8</page-range>. <pub-id pub-id-type="doi">10.1038/10379</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Marchant</surname><given-names>JS</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group>
<article-title>Cell biology of the human thiamine transporter-1 (hTHTR1)</article-title>. <source/>J Biol Chem (<year>2003</year>) <volume>278</volume>:<page-range>3976–84</page-range>. <pub-id pub-id-type="doi">10.1074/jbc.M210717200</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Marchant</surname><given-names>JS</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group>
<article-title>Targeting and trafficking of the human thiamine transporter-2 in epithelial cells</article-title>. <source/>J Biol Chem (<year>2006</year>) <volume>281</volume>:<page-range>5233–45</page-range>. <pub-id pub-id-type="doi">10.1074/jbc.M512765200</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ganapathy</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Prasad</surname><given-names>PD</given-names></name></person-group>
<article-title>SLC19: the folate/thiamine transporter family</article-title>. <source/>Pflugers Arch (<year>2004</year>) <volume>447</volume>:<page-range>641–6</page-range>. <pub-id pub-id-type="doi">10.1007/s00424-003-1068-1</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Frank</surname><given-names>EL</given-names></name></person-group>
<article-title>Rapid HPLC measurement of thiamine and its phosphate esters in whole blood</article-title>. <source/>Clin Chem (<year>2008</year>) <volume>54</volume>:<page-range>901–6</page-range>. <pub-id pub-id-type="doi">10.1373/clinchem.2007.099077</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gangolf</surname><given-names>M</given-names></name><name><surname>Czerniecki</surname><given-names>J</given-names></name><name><surname>Radermecker</surname><given-names>M</given-names></name><name><surname>Detry</surname><given-names>O</given-names></name><name><surname>Nisolle</surname><given-names>M</given-names></name><name><surname>Jouan</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells</article-title>. <source/>PLoS One (<year>2010</year>) <volume>5</volume>:<elocation-id>e13616</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0013616</pub-id>
<pub-id pub-id-type="pmid">21049048</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name><name><surname>Harper</surname><given-names>CG</given-names></name></person-group>
<article-title>Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke–Korsakoff syndrome</article-title>. <source/>Alcohol Clin Exp Res (<year>1993</year>) <volume>17</volume>:<page-range>1084–88</page-range>. <pub-id pub-id-type="doi">10.1111/j.1530-0277.1993.tb05668.x</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name></person-group>
<article-title>Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency</article-title>. <source/>J Neurochem (<year>2009</year>) <volume>111</volume>:<page-range>537–46</page-range>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06341.x</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraccascia</surname><given-names>P</given-names></name><name><surname>Casteels</surname><given-names>M</given-names></name><name><surname>De Schryver</surname><given-names>E</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name></person-group>
<article-title>Role of thiamine pyrophosphate in oligomerisation, functioning and import of peroxisomal 2-hydroxyacyl-CoA lyase</article-title>. <source/>Biochim Biophys Acta (<year>2011</year>) <volume>1814</volume>:<page-range>1226–33</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2011.06.007</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraccascia</surname><given-names>P</given-names></name><name><surname>Sniekers</surname><given-names>M</given-names></name><name><surname>Casteels</surname><given-names>M</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name></person-group>
<article-title>Presence of thiamine pyrophosphate in mammalian peroxisomes</article-title>. <source/>BMC Biochem (<year>2007</year>) <volume>8</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2091-8-10</pub-id>
<pub-id pub-id-type="pmid">17596263</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foulon</surname><given-names>V</given-names></name><name><surname>Antonenkov</surname><given-names>VD</given-names></name><name><surname>Croes</surname><given-names>K</given-names></name><name><surname>Waelkens</surname><given-names>E</given-names></name><name><surname>Mannaerts</surname><given-names>GP</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name><etal></etal></person-group>
<article-title>Purification, molecular cloning, and expression of 2-hydroxyphytanoyl-CoA lyase, a peroxisomal thiamine pyrophosphate-dependent enzyme that catalyzes the carbon-carbon bond cleavage during alpha-oxidation of 3-methyl-branched fatty acids</article-title>. <source/>Proc Natl Acad Sci U S A (<year>1999</year>) <volume>96</volume>:<page-range>10039–44</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.96.18.10039</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watkins</surname><given-names>PA</given-names></name><name><surname>Howard</surname><given-names>AE</given-names></name><name><surname>Mihalik</surname><given-names>SJ</given-names></name></person-group>
<article-title>Phytanic acid must be activated to phytanoyl-CoA prior to its alpha-oxidation in rat liver peroxisomes</article-title>. <source/>Biochim Biophys Acta (<year>1994</year>) <volume>1214</volume>:<page-range>288–94</page-range>. <pub-id pub-id-type="doi">10.1016/0005-2760(94)90075-2</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van den Brink</surname><given-names>DM</given-names></name><name><surname>Wanders</surname><given-names>RJ</given-names></name></person-group>
<article-title>Phytanic acid: production from phytol, its breakdown and role in human disease</article-title>. <source/>Cell Mol Life Sci (<year>2006</year>) <volume>63</volume>:<page-range>1752–65</page-range>. <pub-id pub-id-type="doi">10.1007/s00018-005-5463-y</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skjeldal</surname><given-names>OH</given-names></name><name><surname>Stokke</surname><given-names>O</given-names></name><name><surname>Refsum</surname><given-names>S</given-names></name><name><surname>Norseth</surname><given-names>J</given-names></name><name><surname>Petit</surname><given-names>H</given-names></name></person-group>
<article-title>Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation</article-title>. <source/>J Neurol Sci (<year>1987</year>) <volume>77</volume>:<fpage>87</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/0022-510X(87)90209-7</pub-id>
<pub-id pub-id-type="pmid">2433405</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wierzbicki</surname><given-names>AS</given-names></name><name><surname>Lloyd</surname><given-names>MD</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><name><surname>Feher</surname><given-names>MD</given-names></name><name><surname>Gibberd</surname><given-names>FB</given-names></name></person-group>
<article-title>Refsum’s disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation</article-title>. <source/>J Neurochem (<year>2002</year>) <volume>80</volume>:<page-range>727–35</page-range>. <pub-id pub-id-type="doi">10.1046/j.0022-3042.2002.00766.x</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindhurst</surname><given-names>MJ</given-names></name><name><surname>Fiermonte</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Struys</surname><given-names>E</given-names></name><name><surname>De Leonardis</surname><given-names>F</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><etal></etal></person-group>
<article-title>Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2006</year>) <volume>103</volume>:<page-range>15927–32</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0607661103</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Randle</surname><given-names>PJ</given-names></name><name><surname>Garland</surname><given-names>PB</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name><name><surname>Newsholme</surname><given-names>EA</given-names></name></person-group>
<article-title>The glucose fatty-acid cycle</article-title>. <source/>Lancet (<year>1963</year>) <volume>1</volume>:<page-range>785–89</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(63)91500-9</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muoio</surname><given-names>DM</given-names></name></person-group>
<article-title>Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock</article-title>. <source/>Cell (<year>2014</year>) <volume>159</volume>:<page-range>1253–62</page-range>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.034</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jankowska-Kulawy</surname><given-names>A</given-names></name><name><surname>Bielarczyk</surname><given-names>H</given-names></name><name><surname>Pawelczyk</surname><given-names>T</given-names></name><name><surname>Wroblewska</surname><given-names>M</given-names></name><name><surname>Szutowicz</surname><given-names>A</given-names></name></person-group>
<article-title>Acetyl-CoA deficit in brain mitochondria in experimental thiamine deficiency encephalopathy</article-title>. <source/>Neurochem Int (<year>2010</year>) <volume>57</volume>:<page-range>851–56</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuint.2010.09.003</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Brown</surname><given-names>RM</given-names></name><name><surname>Scholem</surname><given-names>RD</given-names></name><name><surname>Kirby</surname><given-names>DM</given-names></name><name><surname>Dahl</surname><given-names>HH</given-names></name></person-group>
<article-title>The clinical and biochemical spectrum of human pyruvate dehydrogenase complex deficiency</article-title>. <source/>Ann N Y Acad Sci (<year>1989</year>) <volume>573</volume>:<page-range>360–8</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1989.tb15011.x</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Meirleir</surname><given-names>L</given-names></name></person-group>
<article-title>Disorders of pyruvate metabolism</article-title>. <source/>Handb Clin Neurol (<year>2013</year>) <volume>113</volume>:<page-range>1667–73</page-range>. <pub-id pub-id-type="doi">10.1016/B978-0-444-59565-2.00034-4</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gibson</surname><given-names>GE</given-names></name><name><surname>Blass</surname><given-names>JP</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Bunik</surname><given-names>V</given-names></name></person-group>
<article-title>The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration</article-title>. <source/>Mol Neurobiol (<year>2005</year>) <volume>31</volume>:<fpage>43</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1385/MN:31:1-3:043</pub-id>
<pub-id pub-id-type="pmid">15953811</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Karuppagounder</surname><given-names>SS</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Pechman</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Gibson</surname><given-names>GE</given-names></name></person-group>
<article-title>Responses of the mitochondrial alpha-ketoglutarate dehydrogenase complex to thiamine deficiency may contribute to regional selective vulnerability</article-title>. <source/>Neurochem Int (<year>2007</year>) <volume>50</volume>:<page-range>921–31</page-range>. <pub-id pub-id-type="doi">10.1016/j.neuint.2007.03.010</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sperringer</surname><given-names>JE</given-names></name><name><surname>Addington</surname><given-names>A</given-names></name><name><surname>Hutson</surname><given-names>SM</given-names></name></person-group>
<article-title>Branched-chain amino acids and brain metabolism</article-title>. <source/>Neurochem Res (<year>2017</year>) <volume>42</volume>:<page-range>1697–709</page-range>. <pub-id pub-id-type="doi">10.1007/s11064-017-2261-5</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Navarro</surname><given-names>D</given-names></name><name><surname>Zwingmann</surname><given-names>C</given-names></name><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group>
<article-title>Impaired oxidation of branched-chain amino acids in the medial thalamus of thiamine-deficient rats</article-title>. <source/>Metab Brain Dis (<year>2008</year>) <volume>23</volume>:<page-range>445–55</page-range>. <pub-id pub-id-type="doi">10.1007/s11011-008-9105-6</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prohaska</surname><given-names>JR</given-names></name><name><surname>Bailey</surname><given-names>WR</given-names></name></person-group>
<article-title>Persistent regional changes in brain copper, cuproenzymes and catecholamines following perinatal copper deficiency in mice</article-title>. <source/>J Nutr (<year>1993</year>) <volume>123</volume>:<page-range>1226–34</page-range>. <pub-id pub-id-type="doi">10.1093/jn/123.7.1226</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kril</surname><given-names>JJ</given-names></name><name><surname>Harper</surname><given-names>CG</given-names></name></person-group>
<article-title>Neuroanatomy and neuropathology associated with Korsakoff’s syndrome</article-title>. <source/>Neuropsychol Rev (<year>2012</year>) <volume>22</volume>:<fpage>72</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s11065-012-9195-0</pub-id>
<pub-id pub-id-type="pmid">22528862</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Gelin</surname><given-names>G</given-names></name><name><surname>De Surgeloose</surname><given-names>D</given-names></name><name><surname>Palmers</surname><given-names>Y</given-names></name></person-group>
<article-title>Wernicke encephalopathy: MR findings in two patients</article-title>. <source/>Eur Radiol (<year>1999</year>) <volume>9</volume>:<page-range>1620–4</page-range>. <pub-id pub-id-type="doi">10.1007/s003300050896</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kornreich</surname><given-names>L</given-names></name><name><surname>Bron-Harlev</surname><given-names>E</given-names></name><name><surname>Hoffmann</surname><given-names>C</given-names></name><name><surname>Schwarz</surname><given-names>M</given-names></name><name><surname>Konen</surname><given-names>O</given-names></name><name><surname>Schoenfeld</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Thiamine deficiency in infants: MR findings in the brain</article-title>. <source/>AJNR Am J Neuroradiol (<year>2005</year>) <volume>26</volume>:<page-range>1668–74</page-range>. </mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vernau</surname><given-names>KM</given-names></name><name><surname>Runstadler</surname><given-names>JA</given-names></name><name><surname>Brown</surname><given-names>EA</given-names></name><name><surname>Cameron</surname><given-names>JM</given-names></name><name><surname>Huson</surname><given-names>HJ</given-names></name><name><surname>Higgins</surname><given-names>RJ</given-names></name><etal></etal></person-group>
<article-title>Genome-wide association analysis identifies a mutation in the thiamine transporter 2 (SLC19A3) gene associated with Alaskan Husky encephalopathy</article-title>. <source/>PLoS One (<year>2013</year>) <volume>8</volume>:<elocation-id>e57195</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0057195</pub-id>
<pub-id pub-id-type="pmid">23469184</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robinson</surname><given-names>BH</given-names></name></person-group>
<article-title>Prenatal diagnosis of disorders of energy metabolism</article-title>. <source/>Semin Neurol (<year>2001</year>) <volume>21</volume>:<page-range>269–73</page-range>. <pub-id pub-id-type="doi">10.1055/s-2001-17944</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mezzar</surname><given-names>S</given-names></name><name><surname>De Schryver</surname><given-names>E</given-names></name><name><surname>Asselberghs</surname><given-names>S</given-names></name><name><surname>Meyhi</surname><given-names>E</given-names></name><name><surname>Morvay</surname><given-names>PL</given-names></name><name><surname>Baes</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Phytol-induced pathology in 2-hydroxyacyl-CoA lyase (HACL1) deficient mice</article-title>. <source/>Biochim Biophys Acta Mol Cell Biol Lipids (<year>2017</year>) <volume>1862</volume>:<page-range>972–90</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2017.06.004</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foulon</surname><given-names>V</given-names></name><name><surname>Sniekers</surname><given-names>M</given-names></name><name><surname>Huysmans</surname><given-names>E</given-names></name><name><surname>Asselberghs</surname><given-names>S</given-names></name><name><surname>Mahieu</surname><given-names>V</given-names></name><name><surname>Mannaerts</surname><given-names>GP</given-names></name><etal></etal></person-group>
<article-title>Breakdown of 2-hydroxylated straight chain fatty acids <italic>via</italic> peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the alpha-oxidation of straight chain fatty acids</article-title>. <source/>J Biol Chem (<year>2005</year>) <volume>280</volume>:<page-range>9802–12</page-range>. <pub-id pub-id-type="doi">10.1074/jbc.M413362200</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>A</given-names></name></person-group>
<article-title>Phytosphingosine degradation pathway includes fatty acid alpha-oxidation reactions in the endoplasmic reticulum</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2017</year>) <volume>114</volume>:E2616–E<fpage>2623</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.1700138114</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Friesen</surname><given-names>MD</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Wareham</surname><given-names>N</given-names></name></person-group>
<article-title>Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study</article-title>. <source/>PLoS Med (<year>2012</year>) <fpage>9</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001255</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forouhi</surname><given-names>NG</given-names></name><name><surname>Koulman</surname><given-names>A</given-names></name><name><surname>Sharp</surname><given-names>SJ</given-names></name><name><surname>Imamura</surname><given-names>F</given-names></name><name><surname>Kroger</surname><given-names>J</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><etal></etal></person-group>
<article-title>Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study</article-title>. <source/>Lancet Diab Endocrin (<year>2014</year>) <volume>2</volume>:<page-range>810–18</page-range>. <pub-id pub-id-type="doi">10.1016/S2213-8587(14)70146-9</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Diaz</surname><given-names>GA</given-names></name></person-group>
<article-title>Thiamine-responsive megaloblastic anemia syndrome</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>GeneReviews((R)). <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name> (<year>1993</year>).</mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Tabarki</surname><given-names>B</given-names></name><name><surname>Al-Hashem</surname><given-names>A</given-names></name><name><surname>Alfadhel</surname><given-names>M</given-names></name></person-group>
<article-title>Biotin-thiamine-responsive basal ganglia disease</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>GeneReviews((R)). <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name> (<year>1993</year>). p. <fpage>1993</fpage>–<lpage>2019</lpage>. </mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfadhel</surname><given-names>M</given-names></name><name><surname>Almuntashri</surname><given-names>M</given-names></name><name><surname>Jadah</surname><given-names>RH</given-names></name><name><surname>Bashiri</surname><given-names>FA</given-names></name><name><surname>Al Rifai</surname><given-names>MT</given-names></name><name><surname>Al Shalaan</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases</article-title>. <source/>Orphanet J Rare Dis (<year>2013</year>) <volume>8</volume>:<fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/1750-1172-8-83</pub-id>
<pub-id pub-id-type="pmid">23742248</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Biesecker</surname><given-names>LG</given-names></name></person-group>
<article-title>Amish lethal microcephaly</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>GeneReviews((R)). <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name> (<year>1993</year>). </mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siu</surname><given-names>VM</given-names></name><name><surname>Ratko</surname><given-names>S</given-names></name><name><surname>Prasad</surname><given-names>AN</given-names></name><name><surname>Prasad</surname><given-names>C</given-names></name><name><surname>Rupar</surname><given-names>CA</given-names></name></person-group>
<article-title>Amish microcephaly: long-term survival and biochemical characterization</article-title>. <source/>Am J Med Genet A (<year>2010</year>) <volume>152A</volume>:<page-range>1747–51</page-range>. <pub-id pub-id-type="doi">10.1002/ajmg.a.33373</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>R</given-names></name><name><surname>Shaag</surname><given-names>A</given-names></name><name><surname>Edvardson</surname><given-names>S</given-names></name><name><surname>Mandel</surname><given-names>H</given-names></name><name><surname>Stepensky</surname><given-names>P</given-names></name><name><surname>Shalev</surname><given-names>SA</given-names></name><etal></etal></person-group>
<article-title>SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis</article-title>. <source/>Ann Neurol (<year>2009</year>) <volume>66</volume>:<page-range>419–24</page-range>. <pub-id pub-id-type="doi">10.1002/ana.21752</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayr</surname><given-names>JA</given-names></name><name><surname>Freisinger</surname><given-names>P</given-names></name><name><surname>Schlachter</surname><given-names>K</given-names></name><name><surname>Rolinski</surname><given-names>B</given-names></name><name><surname>Zimmermann</surname><given-names>FA</given-names></name><name><surname>Scheffner</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway</article-title>. <source/>Am J Hum Genet (<year>2011</year>) <volume>89</volume>:<page-range>806–12</page-range>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2011.11.007</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banka</surname><given-names>S</given-names></name><name><surname>de Goede</surname><given-names>C</given-names></name><name><surname>Yue</surname><given-names>WW</given-names></name><name><surname>Morris</surname><given-names>AA</given-names></name><name><surname>von Bremen</surname><given-names>B</given-names></name><name><surname>Chandler</surname><given-names>KE</given-names></name><etal></etal></person-group>
<article-title>Expanding the clinical and molecular spectrum of thiamine pyrophosphokinase deficiency: a treatable neurological disorder caused by TPK1 mutations</article-title>. <source/>Mol Genet Metab (<year>2014</year>) <volume>113</volume>:<page-range>301–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2014.09.010</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfadhel</surname><given-names>M</given-names></name><name><surname>Babiker</surname><given-names>A</given-names></name></person-group>
<article-title>Inborn errors of metabolism associated with hyperglycaemic ketoacidosis and diabetes mellitus: narrative review</article-title>. <source/>Sudan J Paediatr (<year>2018</year>) <volume>18</volume>:<fpage>10</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.24911/SJP.2018.1.3</pub-id>
<pub-id pub-id-type="pmid">30166758</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lorber</surname><given-names>A</given-names></name><name><surname>Gazit</surname><given-names>AZ</given-names></name><name><surname>Khoury</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>Y</given-names></name><name><surname>Mandel</surname><given-names>H</given-names></name></person-group>
<article-title>Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome</article-title>. <source/>Pediatr Cardiol (<year>2003</year>) <volume>24</volume>:<page-range>476–81</page-range>. <pub-id pub-id-type="doi">10.1007/s00246-002-0215-3</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ganie</surname><given-names>MA</given-names></name><name><surname>Ali</surname><given-names>I</given-names></name><name><surname>Ahangar</surname><given-names>AG</given-names></name><name><surname>Wani</surname><given-names>MM</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Bhat</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Thiamine responsive megaloblastic anemia syndrome associated with patent ductus arteriosus: first case report from Kashmir Valley of the Indian subcontinent</article-title>. <source/>Indian J Endocrinol Metab (<year>2012</year>) <volume>16</volume>:<page-range>646–50</page-range>. <pub-id pub-id-type="doi">10.4103/2230-8210.98033</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aljabri</surname><given-names>MF</given-names></name><name><surname>Kamal</surname><given-names>NM</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>AlQaedi</surname><given-names>AM</given-names></name><name><surname>Santali</surname><given-names>EY</given-names></name></person-group>
<article-title>A case report of biotin-thiamine-responsive basal ganglia disease in a Saudi child: is extended genetic family study recommended</article-title>? <source/>Medicine (Baltimore) (<year>2016</year>) <volume>95</volume>:<elocation-id>e4819</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000004819</pub-id>
<pub-id pub-id-type="pmid">27749535</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelley</surname><given-names>RI</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Puffenberger</surname><given-names>EG</given-names></name><name><surname>Strauss</surname><given-names>KA</given-names></name><name><surname>Morton</surname><given-names>DH</given-names></name></person-group>
<article-title>Amish lethal microcephaly: a new metabolic disorder with severe congenital microcephaly and 2-ketoglutaric aciduria</article-title>. <source/>Am J Med Genet (<year>2002</year>) <volume>112</volume>:<page-range>318–26</page-range>. <pub-id pub-id-type="doi">10.1002/ajmg.10529</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraser</surname><given-names>JL</given-names></name><name><surname>Vanderver</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>T</given-names></name><name><surname>Cramp</surname><given-names>L</given-names></name><name><surname>Vezina</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Thiamine pyrophosphokinase deficiency causes a Leigh disease like phenotype in a sibling pair: identification through whole exome sequencing and management strategies</article-title>. <source/>Mol Genet Metab Rep (<year>2014</year>) <volume>1</volume>:<fpage>66</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgmr.2013.12.007</pub-id>
<pub-id pub-id-type="pmid">27896076</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Sidiropoulos</surname><given-names>C</given-names></name></person-group>
<article-title>TPK1 mutation induced childhood onset idiopathic generalized dystonia: report of a rare mutation and effect of deep brain stimulation</article-title>. <source/>J Neurol Sci (<year>2017</year>) <volume>376</volume>:<page-range>42–3</page-range>. <pub-id pub-id-type="doi">10.1016/j.jns.2017.02.063</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murata</surname><given-names>T</given-names></name></person-group>
<article-title>Influence of thiamine on the amount of lactic acid in urine</article-title>. <source/>J Vitaminol (Kyoto) (<year>1958</year>) <volume>4</volume>:<page-range>109–13</page-range>. <pub-id pub-id-type="doi">10.5925/jnsv1954.4.109</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wendel</surname><given-names>OW</given-names></name></person-group>
<article-title>A study of urinary lactic acid levels in humans</article-title>. <source/>J Vitaminol (Kyoto) (<year>1960</year>) <volume>6</volume>:<fpage>16</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.5925/jnsv1954.6.16</pub-id>
<pub-id pub-id-type="pmid">13843946</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Israels</surname><given-names>S</given-names></name><name><surname>Haworth</surname><given-names>JC</given-names></name><name><surname>Dunn</surname><given-names>HG</given-names></name><name><surname>Applegarth</surname><given-names>DA</given-names></name></person-group>
<article-title>Lactic acidosis in childhood</article-title>. <source/>Adv Pediatr (<year>1976</year>) <volume>22</volume>:<fpage>267</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="pmid">178159</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweet</surname><given-names>RL</given-names></name><name><surname>Zastre</surname><given-names>JA</given-names></name></person-group>
<article-title>HIF1-alpha-mediated gene expression induced by vitamin B1 deficiency</article-title>. <source/>Int J Vitam Nutr Res (<year>2013</year>) <volume>83</volume>:<page-range>188–97</page-range>. <pub-id pub-id-type="doi">10.1024/0300-9831/a000159</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Attwell</surname><given-names>D</given-names></name><name><surname>Laughlin</surname><given-names>SB</given-names></name></person-group>
<article-title>An energy budget for signaling in the grey matter of the brain</article-title>. <source/>J Cereb Blood Flow Metab (<year>2001</year>) <volume>21</volume>:<page-range>1133–45</page-range>. <pub-id pub-id-type="doi">10.1097/00004647-200110000-00001</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mergenthaler</surname><given-names>P</given-names></name><name><surname>Lindauer</surname><given-names>U</given-names></name><name><surname>Dienel</surname><given-names>GA</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name></person-group>
<article-title>Sugar for the brain: the role of glucose in physiological and pathological brain function</article-title>. <source/>Trends Neurosci (<year>2013</year>) <volume>36</volume>:<page-range>587–97</page-range>. <pub-id pub-id-type="doi">10.1016/j.tins.2013.07.001</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karabatsiakis</surname><given-names>A</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Salinas-Manrique</surname><given-names>J</given-names></name><name><surname>Kolassa</surname><given-names>S</given-names></name><name><surname>Calzia</surname><given-names>E</given-names></name><name><surname>Dietrich</surname><given-names>DE</given-names></name><etal></etal></person-group>
<article-title>Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression</article-title>. <source/>Transl Psychiatry (<year>2014</year>) <volume>4</volume>:e<fpage>397</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2014.44</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>S</given-names></name><name><surname>Swatton</surname><given-names>JE</given-names></name><name><surname>Ryan</surname><given-names>MM</given-names></name><name><surname>Huffaker</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>JT</given-names></name><name><surname>Griffin</surname><given-names>JL</given-names></name><etal></etal></person-group>
<article-title>Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress</article-title>. <source/>Mol Psych (<year>2004</year>) <volume>9</volume>:<page-range>684-97</page-range>643. <pub-id pub-id-type="doi">10.1038/sj.mp.4001511</pub-id>
</mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Sang</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name></person-group>
<article-title>Thiamine metabolism is critical for regulating correlated growth of dendrite arbors and neuronal somata</article-title>. <source/>Sci Rep (<year>2017</year>) <volume>7</volume>:<fpage>5342</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-05476-w</pub-id>
<pub-id pub-id-type="pmid">28706281</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>MF</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name></person-group>
<article-title>Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer’s type</article-title>. <source/>Arch Neurol (<year>1995</year>) <volume>52</volume>:<page-range>1081–86</page-range>. <pub-id pub-id-type="doi">10.1001/archneur.1995.00540350075019</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitfield</surname><given-names>KC</given-names></name><name><surname>Bourassa</surname><given-names>MW</given-names></name><name><surname>Adamolekun</surname><given-names>B</given-names></name><name><surname>Bergeron</surname><given-names>G</given-names></name><name><surname>Bettendorff</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>KH</given-names></name><etal></etal></person-group>
<article-title>Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs</article-title>. <source/>Ann N Y Acad Sci (<year>2018</year>) <volume>1430</volume>:<fpage>3</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.13919</pub-id>
<pub-id pub-id-type="pmid">30151974</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molina</surname><given-names>JA</given-names></name><name><surname>Jimenez-Jimenez</surname><given-names>FJ</given-names></name><name><surname>Hernanz</surname><given-names>A</given-names></name><name><surname>Fernandez-Vivancos</surname><given-names>E</given-names></name><name><surname>Medina</surname><given-names>S</given-names></name><name><surname>de Bustos</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Cerebrospinal fluid levels of thiamine in patients with Alzheimer’s disease</article-title>. <source/>J Neural Transm (Vienna) (<year>2002</year>) <volume>109</volume>:<page-range>1035–44</page-range>. <pub-id pub-id-type="doi">10.1007/s007020200087</pub-id>
</mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortigoza-Escobar</surname><given-names>JD</given-names></name><name><surname>Molero-Luis</surname><given-names>M</given-names></name><name><surname>Arias</surname><given-names>A</given-names></name><name><surname>Oyarzabal</surname><given-names>A</given-names></name><name><surname>Darin</surname><given-names>N</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome</article-title>. <source/>Brain (<year>2016</year>) <volume>139</volume>:<page-range>31–8</page-range>. <pub-id pub-id-type="doi">10.1093/brain/awv342</pub-id>
</mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Magos</surname><given-names>L</given-names></name></person-group>
<article-title>Geigy scientific tables</article-title>. In: <person-group person-group-type="editor"><name><surname>Lentner</surname><given-names>C</given-names></name></person-group>, editor. <source/>Units of measurement. Body fluids. Composition of the body. Nutrition, <edition>8th ed</edition>
<publisher-loc>West Cadwell, N.J.</publisher-loc> (<year>1987</year>). p. <page-range>165–77</page-range>. </mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fattal-Valevski</surname><given-names>A</given-names></name></person-group>
<article-title>Thiamine (vitamin B1)</article-title>. <source/>J Evidence-Based Compl Alt Med (<year>2011</year>) <volume>16</volume>:<fpage>12</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1177/1533210110392941</pub-id>
</mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>WHO</collab></person-group>
<article-title>International nomenclature of diseases</article-title>. In: <source/>Metabolic, nutritional, and endocrine disorders, (<year>1991</year>). p. <fpage>278</fpage>. </mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>RR</given-names></name></person-group>
<article-title>The classical deficiency diseases</article-title>. <source/>Fed Proc (<year>1961</year>) <volume>20</volume>(<issue>Suppl 7</issue>):<page-range>323–27</page-range>. </mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mulholland</surname><given-names>PJ</given-names></name></person-group>
<article-title>Susceptibility of the cerebellum to thiamine deficiency</article-title>. <source/>Cerebellum (<year>2006</year>) <volume>5</volume>:<fpage>55</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1080/14734220600551707</pub-id>
<pub-id pub-id-type="pmid">16527765</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nardone</surname><given-names>R</given-names></name><name><surname>Holler</surname><given-names>Y</given-names></name><name><surname>Storti</surname><given-names>M</given-names></name><name><surname>Christova</surname><given-names>M</given-names></name><name><surname>Tezzon</surname><given-names>F</given-names></name><name><surname>Golaszewski</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Thiamine deficiency induced neurochemical, neuroanatomical, and neuropsychological alterations: a reappraisal</article-title>. <source/>Sci World J (<year>2013</year>) <volume>2013</volume>:<elocation-id>309143</elocation-id>. <pub-id pub-id-type="doi">10.1155/2013/309143</pub-id>
</mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inaba</surname><given-names>H</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Oishi</surname><given-names>S</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Vitamin B1-deficient mice show impairment of hippocampus-dependent memory formation and loss of hippocampal neurons and dendritic spines: potential microendophenotypes of Wernicke–Korsakoff syndrome</article-title>. <source/>Biosci Biotechnol Biochem (<year>2016</year>) <volume>80</volume>:<page-range>2425–36</page-range>. <pub-id pub-id-type="doi">10.1080/09168451.2016.1224639</pub-id>
</mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Stargrove</surname><given-names>MB</given-names></name><name><surname>Treasure</surname><given-names>J</given-names></name><name><surname>McKee</surname><given-names>DL</given-names></name></person-group>
<source/>Herb, nutrient, and drug interactions: clinical implications and therapeutic strategies. <publisher-loc>St. Louis (MO)</publisher-loc>: <publisher-name>Mosby/Elsevier</publisher-name> (<year>2008</year>). p. <fpage>255</fpage>. </mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AD</given-names></name><name><surname>Marshall</surname><given-names>EJ</given-names></name></person-group>
<article-title>The treatment of patients at risk of developing Wernicke’s encephalopathy in the community</article-title>. <source/>Alcohol (<year>2006</year>) <volume>41</volume>:<page-range>159–67</page-range>. <pub-id pub-id-type="doi">10.1093/alcalc/agh250</pub-id>
</mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galvin</surname><given-names>R</given-names></name><name><surname>Brathen</surname><given-names>G</given-names></name><name><surname>Ivashynka</surname><given-names>A</given-names></name><name><surname>Hillbom</surname><given-names>M</given-names></name><name><surname>Tanasescu</surname><given-names>R</given-names></name><name><surname>Leone</surname><given-names>MA</given-names></name></person-group>
<article-title>EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy</article-title>. <source/>Eur J Neurol (<year>2010</year>) <volume>17</volume>:<page-range>1408–18</page-range>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03153.x</pub-id>
</mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arts</surname><given-names>NJ</given-names></name><name><surname>Walvoort</surname><given-names>SJ</given-names></name><name><surname>Kessels</surname><given-names>RP</given-names></name></person-group>
<article-title>Korsakoff’s syndrome: a critical review</article-title>. <source/>Neuropsychiatr Dis Treat (<year>2017</year>) <volume>13</volume>:<page-range>2875–90</page-range>. <pub-id pub-id-type="doi">10.2147/NDT.S130078</pub-id>
</mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Day</surname><given-names>GS</given-names></name><name><surname>Del Campo</surname><given-names>CM</given-names></name></person-group>
<article-title>Wernicke encephalopathy: a medical emergency</article-title>. <source/>CMAJ (<year>2014</year>) <volume>186</volume>:<fpage>E295</fpage>. <pub-id pub-id-type="doi">10.1503/cmaj.130091</pub-id>
<pub-id pub-id-type="pmid">24016788</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuccoli</surname><given-names>G</given-names></name><name><surname>Siddiqui</surname><given-names>N</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Bartoletti</surname><given-names>SC</given-names></name></person-group>
<article-title>Neuroimaging findings in pediatric Wernicke encephalopathy: a review</article-title>. <source/>Neuroradiol (<year>2010</year>) <volume>52</volume>:<page-range>523–29</page-range>. <pub-id pub-id-type="doi">10.1007/s00234-009-0604-x</pub-id>
</mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>Thiamine nutritional status and depressive symptoms are inversely associated among older Chinese adults</article-title>. <source/>J Nutr (<year>2013</year>) <volume>143</volume>:<page-range>53–8</page-range>. <pub-id pub-id-type="doi">10.3945/jn.112.167007</pub-id>
</mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carney</surname><given-names>MW</given-names></name><name><surname>Williams</surname><given-names>DG</given-names></name><name><surname>Sheffield</surname><given-names>BF</given-names></name></person-group>
<article-title>Thiamine and pyridoxine lack newly-admitted psychiatric patients</article-title>. <source/>Br J Psychiatry (<year>1979</year>) <volume>135</volume>:<page-range>249–54</page-range>. <pub-id pub-id-type="doi">10.1192/bjp.135.3.249</pub-id>
</mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pepersack</surname><given-names>T</given-names></name><name><surname>Garbusinski</surname><given-names>J</given-names></name><name><surname>Robberecht</surname><given-names>J</given-names></name><name><surname>Beyer</surname><given-names>I</given-names></name><name><surname>Willems</surname><given-names>D</given-names></name><name><surname>Fuss</surname><given-names>M</given-names></name></person-group>
<article-title>Clinical relevance of thiamine status amongst hospitalized elderly patients</article-title>. <source/>Gerontology (<year>1999</year>) <volume>45</volume>:<fpage>96</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1159/000022070</pub-id>
<pub-id pub-id-type="pmid">9933732</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghaleiha</surname><given-names>A</given-names></name><name><surname>Davari</surname><given-names>H</given-names></name><name><surname>Jahangard</surname><given-names>L</given-names></name><name><surname>Haghighi</surname><given-names>M</given-names></name><name><surname>Ahmadpanah</surname><given-names>M</given-names></name><name><surname>Seifrabie</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial</article-title>. <source/>Eur Arch Psychiatry Clin Neurosci (<year>2016</year>) <volume>266</volume>:<fpage>695</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-016-0685-6</pub-id>
<pub-id pub-id-type="pmid">26984349</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benton</surname><given-names>D</given-names></name><name><surname>Griffiths</surname><given-names>R</given-names></name><name><surname>Haller</surname><given-names>J</given-names></name></person-group>
<article-title>Thiamine supplementation mood and cognitive functioning</article-title>. <source/>Psychopharmacology (<year>1997</year>) <volume>129</volume>:<fpage>66</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/s002130050163</pub-id>
<pub-id pub-id-type="pmid">9122365</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fattal-Valevski</surname><given-names>A</given-names></name><name><surname>Azouri-Fattal</surname><given-names>I</given-names></name><name><surname>Greenstein</surname><given-names>YJ</given-names></name><name><surname>Guindy</surname><given-names>M</given-names></name><name><surname>Blau</surname><given-names>A</given-names></name><name><surname>Zelnik</surname><given-names>N</given-names></name></person-group>
<article-title>Delayed language development due to infantile thiamine deficiency</article-title>. <source/>Dev Med Child Neurol (<year>2009</year>) <volume>51</volume>:<page-range>629–34</page-range>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2008.03161.x</pub-id>
</mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mimouni-Bloch</surname><given-names>A</given-names></name><name><surname>Goldberg-Stern</surname><given-names>H</given-names></name><name><surname>Strausberg</surname><given-names>R</given-names></name><name><surname>Brezner</surname><given-names>A</given-names></name><name><surname>Heyman</surname><given-names>E</given-names></name><name><surname>Inbar</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Thiamine deficiency in infancy: long-term follow-up</article-title>. <source/>Pediatr Neurol (<year>2014</year>) <volume>51</volume>:<page-range>311–16</page-range>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.05.010</pub-id>
</mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Harel</surname><given-names>Y</given-names></name><name><surname>Zuk</surname><given-names>L</given-names></name><name><surname>Guindy</surname><given-names>M</given-names></name><name><surname>Nakar</surname><given-names>O</given-names></name><name><surname>Lotan</surname><given-names>D</given-names></name><name><surname>Fattal-Valevski</surname><given-names>A</given-names></name></person-group>
<article-title>The effect of subclinical infantile thiamine deficiency on motor function in preschool children</article-title>. <source/>Matern Child Nutr (<year>2017</year>) <fpage>13</fpage>. <pub-id pub-id-type="doi">10.1111/mcn.12397</pub-id>
</mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Kuile</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>HM</given-names></name><name><surname>Allier-Frachon</surname><given-names>I</given-names></name><name><surname>Ohn</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Beri-beri: the major cause of infant mortality in Karen refugees</article-title>. <source/>Trans R Soc Trop Med Hyg (<year>2003</year>) <volume>97</volume>:<page-range>251–5</page-range>. <pub-id pub-id-type="doi">10.1016/S0035-9203(03)90134-9</pub-id>
</mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barennes</surname><given-names>H</given-names></name><name><surname>Sengkhamyong</surname><given-names>K</given-names></name><name><surname>Rene</surname><given-names>JP</given-names></name><name><surname>Phimmasane</surname><given-names>M</given-names></name></person-group>
<article-title>Beriberi (thiamine deficiency) and high infant mortality in northern Laos</article-title>. <source/>PLoS Negl Trop Dis (<year>2015</year>) <volume>9</volume>:<elocation-id>e0003581</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003581</pub-id>
<pub-id pub-id-type="pmid">25781926</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vasconcelos</surname><given-names>MM</given-names></name><name><surname>Silva</surname><given-names>KP</given-names></name><name><surname>Vidal</surname><given-names>G</given-names></name><name><surname>Silva</surname><given-names>AF</given-names></name><name><surname>Domingues</surname><given-names>RC</given-names></name><name><surname>Berditchevsky</surname><given-names>CR</given-names></name></person-group>
<article-title>Early diagnosis of pediatric Wernicke’s encephalopathy</article-title>. <source/>Pediatr Neurol (<year>1999</year>) <volume>20</volume>:<page-range>289–94</page-range>. <pub-id pub-id-type="doi">10.1016/S0887-8994(98)00153-2</pub-id>
</mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfadhel</surname><given-names>M</given-names></name></person-group>
<article-title>Early infantile Leigh-like SLC19A3 gene defects have a poor prognosis: report and review</article-title>. <source/>J Cent Nerv Syst Dis (<year>2017</year>) <volume>9</volume>:<elocation-id>1179573517737521</elocation-id>. <pub-id pub-id-type="doi">10.1177/1179573517737521</pub-id>
<pub-id pub-id-type="pmid">29123435</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez-Duenas</surname><given-names>B</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Rebollo</surname><given-names>M</given-names></name><name><surname>Muchart</surname><given-names>J</given-names></name><name><surname>Gargallo</surname><given-names>E</given-names></name><name><surname>Dupuits</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency</article-title>. <source/>Pediatrics (<year>2013</year>) <volume>131</volume>:<page-range>e1670–1675</page-range>. <pub-id pub-id-type="doi">10.1542/peds.2012-2988</pub-id>
</mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baio</surname><given-names>J</given-names></name><name><surname>Wiggins</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>DL</given-names></name><name><surname>Maenner</surname><given-names>MJ</given-names></name><name><surname>Daniels</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014</article-title>. <source/>MMWR Surveill Summ (<year>2018</year>) <volume>67</volume>:<fpage>1</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.ss6706a1</pub-id>
</mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortega Garcia</surname><given-names>JA</given-names></name><name><surname>Angulo</surname><given-names>MG</given-names></name><name><surname>Sobrino-Najul</surname><given-names>EJ</given-names></name><name><surname>Soldin</surname><given-names>OP</given-names></name><name><surname>Mira</surname><given-names>AP</given-names></name><name><surname>Martinez-Salcedo</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Prenatal exposure of a girl with autism spectrum disorder to ‘horsetail’ (<italic>Equisetum arvense</italic>) herbal remedy and alcohol: a case report</article-title>. <source/>J Med Case Rep (<year>2011</year>) <volume>5</volume>:<fpage>129</fpage>. <pub-id pub-id-type="doi">10.1186/1752-1947-5-129</pub-id>
<pub-id pub-id-type="pmid">21453474</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aronson</surname><given-names>M</given-names></name><name><surname>Hagberg</surname><given-names>B</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name></person-group>
<article-title>Attention deficits and autistic spectrum problems in children exposed to alcohol during gestation: a follow-up study</article-title>. <source/>Dev Med Child Neurol (<year>1997</year>) <volume>39</volume>:<page-range>583–7</page-range>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.1997.tb07493.x</pub-id>
</mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>S</given-names></name><name><surname>Dani</surname><given-names>HM</given-names></name><name><surname>Mahmood</surname><given-names>A</given-names></name></person-group>
<article-title>Effect of dietary thiamin deficiency on intestinal functions in rats</article-title>. <source/>Am J Clin Nutr (<year>1984</year>) <volume>40</volume>:<page-range>226–34</page-range>. <pub-id pub-id-type="doi">10.1093/ajcn/40.2.226</pub-id>
</mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lương</surname><given-names>KVQ</given-names></name><name><surname>Nguyễn</surname><given-names>LTH</given-names></name></person-group>
<article-title>The role of thiamine in autism</article-title>. <source/>Am J Psych Neurosci (<year>2013</year>) <volume>1</volume>:<fpage>22</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.11648/j.ajpn.20130102.11</pub-id>
</mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLure</surname><given-names>KG</given-names></name><name><surname>Takagi</surname><given-names>M</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name></person-group>
<article-title>NAD+ modulates p53 DNA binding specificity and function</article-title>. <source/>Mol Cell Biol (<year>2004</year>) <volume>24</volume>:<page-range>9958–67</page-range>. <pub-id pub-id-type="doi">10.1128/MCB.24.22.9958-9967.2004</pub-id>
</mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name></person-group>
<article-title>The expression of p53, MDM2 and Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or elevated pressure</article-title>. <source/>Yan Ke Xue Bao (<year>2004</year>) <volume>20</volume>:<page-range>259–63</page-range>. </mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishaque</surname><given-names>A</given-names></name><name><surname>Al-Rubeai</surname><given-names>M</given-names></name></person-group>
<article-title>Role of vitamins in determining apoptosis and extent of suppression by bcl-2 during hybridoma cell culture</article-title>. <source/>Apoptosis (<year>2002</year>) <volume>7</volume>:<page-range>231–9</page-range>. <pub-id pub-id-type="doi">10.1023/A:1015343616059</pub-id>
</mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabie</surname><given-names>T</given-names></name><name><surname>Muhlhofer</surname><given-names>W</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Schwab</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>AT</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Transient protective effect of B-vitamins in experimental epilepsy in the mouse brain</article-title>. <source/>J Mol Neurosci (<year>2010</year>) <volume>41</volume>:<page-range>74–9</page-range>. <pub-id pub-id-type="doi">10.1007/s12031-009-9286-4</pub-id>
</mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chornyy</surname><given-names>S</given-names></name><name><surname>Parkhomenko</surname><given-names>J</given-names></name><name><surname>Chorna</surname><given-names>N</given-names></name></person-group>
<article-title>Thiamine deficiency caused by thiamine antagonists triggers upregulation of apoptosis inducing factor gene expression and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-12 cells</article-title>. <source/>Acta Biochim Pol (<year>2007</year>) <volume>54</volume>:<page-range>315–22</page-range>. </mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plaitakis</surname><given-names>A</given-names></name><name><surname>Nicklas</surname><given-names>WJ</given-names></name><name><surname>Berl</surname><given-names>S</given-names></name></person-group>
<article-title>Thiamine deficiency: selective impairment of the cerebellar serotonergic system</article-title>. <source/>Neurology (<year>1978</year>) <volume>28</volume>:<page-range>691–8</page-range>. <pub-id pub-id-type="doi">10.1212/WNL.28.7.691</pub-id>
</mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chugani</surname><given-names>DC</given-names></name><name><surname>Muzik</surname><given-names>O</given-names></name><name><surname>Rothermel</surname><given-names>R</given-names></name><name><surname>Behen</surname><given-names>M</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Mangner</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys</article-title>. <source/>Ann Neurol (<year>1997</year>) <volume>42</volume>:<page-range>666–9</page-range>. <pub-id pub-id-type="doi">10.1002/ana.410420420</pub-id>
</mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lukienko</surname><given-names>PI</given-names></name><name><surname>Mel’nichenko</surname><given-names>NG</given-names></name><name><surname>Zverinskii</surname><given-names>IV</given-names></name><name><surname>Zabrodskaya</surname><given-names>SV</given-names></name></person-group>
<article-title>Antioxidant properties of thiamine</article-title>. <source/>Bull Exp Biol Med (<year>2000</year>) <volume>130</volume>:<page-range>874–6</page-range>. <pub-id pub-id-type="doi">10.1007/BF02682257</pub-id>
</mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Neri</surname><given-names>M</given-names></name><name><surname>Cesario</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>JB</given-names></name><name><surname>Domenici</surname><given-names>E</given-names></name><name><surname>Dalla Bernardina</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Oxidative stress-related biomarkers in autism: systematic review and meta-analyses</article-title>. <source/>Free Radic Biol Med (<year>2012</year>) <volume>52</volume>:<page-range>2128–41</page-range>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.03.011</pub-id>
</mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giulivi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>YF</given-names></name><name><surname>Omanska-Klusek</surname><given-names>A</given-names></name><name><surname>Ross-Inta</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Mitochondrial dysfunction in autism</article-title>. <source/>JAMA (<year>2010</year>) <volume>304</volume>:<page-range>2389–96</page-range>. <pub-id pub-id-type="doi">10.1001/jama.2010.1706</pub-id>
</mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Chauhan</surname><given-names>V</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>WT</given-names></name><name><surname>LaFauci</surname><given-names>G</given-names></name><name><surname>Wegiel</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Alterations in mitochondrial DNA copy number and the activities of electron transport chain complexes and pyruvate dehydrogenase in the frontal cortex from subjects with autism</article-title>. <source/>Transl Psychiatry (<year>2013</year>) <volume>3</volume>:<fpage>e299</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2013.68</pub-id>
<pub-id pub-id-type="pmid">24002085</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anwar</surname><given-names>A</given-names></name><name><surname>Marini</surname><given-names>M</given-names></name><name><surname>Abruzzo</surname><given-names>PM</given-names></name><name><surname>Bolotta</surname><given-names>A</given-names></name><name><surname>Ghezzo</surname><given-names>A</given-names></name><name><surname>Visconti</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls</article-title>. <source/>Free Radic Res (<year>2016</year>) <volume>50</volume>:<fpage>S85</fpage>–<lpage>S90</lpage>. <pub-id pub-id-type="doi">10.1080/10715762.2016.1239821</pub-id>
<pub-id pub-id-type="pmid">27667096</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mulle</surname><given-names>JG</given-names></name><name><surname>Sharp</surname><given-names>WG</given-names></name><name><surname>Cubells</surname><given-names>JF</given-names></name></person-group>
<article-title>The gut microbiome: a new frontier in autism research</article-title>. <source/>Curr Psychiatry Rep (<year>2013</year>) <volume>15</volume>:<fpage>337</fpage>. <pub-id pub-id-type="doi">10.1007/s11920-012-0337-0</pub-id>
<pub-id pub-id-type="pmid">23307560</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lonsdale</surname><given-names>D</given-names></name><name><surname>Shamberger</surname><given-names>RJ</given-names></name><name><surname>Audhya</surname><given-names>T</given-names></name></person-group>
<article-title>Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study</article-title>. <source/>Neuro Endocrinol Lett (<year>2002</year>) <volume>23</volume>:<page-range>303–8</page-range>. </mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Obrenovich</surname><given-names>ME</given-names></name><name><surname>Shamberger</surname><given-names>RJ</given-names></name><name><surname>Lonsdale</surname><given-names>D</given-names></name></person-group>
<article-title>Altered heavy metals and transketolase found in autistic spectrum disorder</article-title>. <source/>Biol Trace Elem Res (<year>2011</year>) <volume>144</volume>:<page-range>475–86</page-range>. <pub-id pub-id-type="doi">10.1007/s12011-011-9146-2</pub-id>
</mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>JB</given-names></name><name><surname>Audhya</surname><given-names>T</given-names></name><name><surname>Donough-Means</surname><given-names>S</given-names></name><name><surname>Rubin</surname><given-names>RA</given-names></name><name><surname>Quig</surname><given-names>D</given-names></name><name><surname>Geis</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Effect of a vitamin/mineral supplement on children and adults with autism</article-title>. <source/>BMC Pediatr (<year>2011</year>) <volume>11</volume>:<fpage>111</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2431-11-111</pub-id>
<pub-id pub-id-type="pmid">22151477</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rubio-Lopez</surname><given-names>N</given-names></name><name><surname>Morales-Suarez-Varela</surname><given-names>M</given-names></name><name><surname>Pico</surname><given-names>Y</given-names></name><name><surname>Livianos-Aldana</surname><given-names>L</given-names></name><name><surname>Llopis-Gonzalez</surname><given-names>A</given-names></name></person-group>
<article-title>Nutrient intake and depression symptoms in Spanish children: the ANIVA study</article-title>. <source/>Int J Environ Res Public Health (<year>2016</year>) <fpage>13</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph13030352</pub-id>
</mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AH</given-names></name><name><surname>Kozloff</surname><given-names>N</given-names></name><name><surname>Sacks</surname><given-names>D</given-names></name></person-group>
<article-title>Pediatric depression: an evidence-based update on treatment interventions</article-title>. <source/>Curr Psychiatry Rep (<year>2013</year>) <volume>15</volume>:<fpage>381</fpage>. <pub-id pub-id-type="doi">10.1007/s11920-013-0381-4</pub-id>
<pub-id pub-id-type="pmid">23881712</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colbert</surname><given-names>P</given-names></name><name><surname>Newman</surname><given-names>B</given-names></name><name><surname>Ney</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>J</given-names></name></person-group>
<article-title>Learning disabilities as a symptom of depression in children</article-title>. <source/>J Learn Disabil (<year>1982</year>) <volume>15</volume>:<page-range>333–6</page-range>. <pub-id pub-id-type="doi">10.1177/002221948201500605</pub-id>
</mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Society</surname><given-names>CP</given-names></name></person-group>
<article-title>Maternal depression and child development</article-title>. <source/>Paediatr Child Health (<year>2004</year>) <volume>9</volume>:<page-range>575–98</page-range>. <pub-id pub-id-type="doi">10.1093/pch/9.8.575</pub-id>
</mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nikseresht</surname><given-names>S</given-names></name><name><surname>Etebary</surname><given-names>S</given-names></name><name><surname>Karimian</surname><given-names>M</given-names></name><name><surname>Nabavizadeh</surname><given-names>F</given-names></name><name><surname>Zarrindast</surname><given-names>MR</given-names></name><name><surname>Sadeghipour</surname><given-names>HR</given-names></name></person-group>
<article-title>Acute administration of Zn, Mg, and thiamine improves postpartum depression conditions in mice</article-title>. <source/>Arch Iran Med (<year>2012</year>) <volume>15</volume>:<page-range>306–11</page-range>. 012155/AIM.0012</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>